Methods for treating cancer with a combination of tucatinib and anti-PD-1 / anti-PD-L1 antibodies

JP2023549581A5Inactive Publication Date: 2024-11-22SEAGEN INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023553164
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-17
Filing Date
2021-11-16
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapies targeting HER2 mutations in cancers are limited by their low frequency, insufficient understanding of biological activity, and difficulty in distinguishing driver and passenger mutations, leading to suboptimal safety and efficacy, particularly in HER2+ solid tumors.

Method used

A combination therapy involving tucatinib, a selective HER2 inhibitor, and anti-PD-1 or anti-PD-L1 antibodies is administered to treat HER2+ solid tumors, including those with mutant forms of HER2, enhancing immune response and tumor suppression.

Benefits of technology

The combination therapy significantly reduces tumor size, improves progression-free and overall survival, and modulates immune cell infiltration, offering a safer and more effective treatment approach for HER2+ cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000095_0000
    Figure 00000095_0000
  • Figure 00000095_0001
    Figure 00000095_0001
  • Figure 00000095_0002
    Figure 00000095_0002
Patent Text Reader

Abstract

The present invention provides a method for treating solid tumors with tucatinib, or a salt or solvate thereof, in combination with an anti-PD-1 antibody or antigen-binding fragment thereof. The present invention also provides a method for treating solid tumors with tucatinib, or a salt or solvate thereof, in combination with an anti-PD-L1 antibody or antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 114,797, filed November 17, 2020, the disclosure of which is incorporated herein by reference for all purposes.

[0002] The present invention relates to a method of treating solid tumors with tucatinib, or a salt or solvate thereof, in combination with an anti-PD-1 antibody or antigen-binding fragment thereof. The present invention also relates to a method of treating solid tumors with tucatinib, or a salt or solvate thereof, in combination with an anti-PD-L1 antibody or antigen-binding fragment thereof. [Background technology]

[0003] Tucatinib ((N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N 6 -(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine) (TUKYSA™; formerly known as ARRY-380 and ONT-380) is a potent and highly selective orally (PO) administered small molecule tyrosine kinase inhibitor (TKI) of HER2. Tucatinib is a potent inhibitor of HER2 in vitro, demonstrating greater than 1000-fold selectivity for HER2 over the closely related EGFR kinase in cell signaling assays. Tucatinib's selectivity for HER2 reduces the potential for EGFR-related toxicity sometimes seen with dual HER2 / EGFR inhibitors. Tucatinib inhibits tumor cell proliferation, survival, and metastasis by inhibiting HER2-driven mitogen-activated protein and PI3 kinase signaling pathways.

[0004] Human epidermal growth factor receptor 2 (HER2), encoded by the ERBB2 gene, is a member of a family of four related receptor tyrosine kinases, including HER1 (also known as epidermal growth factor receptor [EGFR]), HER2, HER3, and HER4. HER1-4 are single-pass transmembrane glycoprotein receptors containing an extracellular ligand-binding domain and an intracellular signaling domain. HER2 has no known ligand but is the preferred dimerization partner for other HER family receptors. When overexpressed in tumors, HER2 forms a ligand-independent homodimeric complex that undergoes autophosphorylation. HER2 homodimerization or heterodimerization leads to the activation of multiple signaling cascades, including the Ras / Raf / MEK / MAPK, PI3K / AKT, Src, and STAT pathways. These signaling pathways lead to cell proliferation, inhibition of apoptosis, and metastasis.

[0005] HER2 is an effective target in multiple solid tumors, and anti-HER2 biologics and anti-HER2 small molecule drugs have been approved for patients with HER2-overexpressed / amplified breast and gastric cancers. Amplification of the HER2 gene or overexpression of its protein occurs in approximately 15% to 20% of breast cancers.

[0006] In typical HER2+ cancers, including breast, gastric, and colon cancers, HER2 amplification leads to robust signaling through either homodimerization or heterodimerization with other ErbB-family members, which activates both downstream MAP kinase and phosphatidylinositol-3 (PI3) kinase pathways, leading to enhanced mitogenesis and survival.

[0007] However, in some cancers, HER2 expression is not amplified; rather, HER2 contains activating mutations in the kinase domain that can confer signal transduction and mitogenesis alike (see WO2018 / 200505). HER2-activating mutations can act as oncogenic drivers in various cancer types (see WO2018 / 200505). Because the majority of these HER2-mutated cancers are not associated with concomitant HER2 gene amplification, an important subgroup of HER2-altered cancers is not detected by immunohistochemistry (IHC) or in situ hybridization (ISH) techniques. Clinically, they can be identified by next-generation sequencing (NGS) of either tumor biopsies or circulating cell-free DNA (cfDNA). Annals of Oncol 28:136-141 (2017). Preclinical data indicate that HER2 "hotspot" mutations can be constitutively active, have transforming potential in vitro and in vivo, and exhibit variable sensitivity to anti-HER2-based therapies. J Mol Diagn, 17(5):487-495(2015), Nat Gen 51, 207-216(2019). Recent clinical trials have also demonstrated the potential activity of HER2-targeted drugs against a variety of tumors harboring HER2 mutations. HER2-targeted agents may be potentially useful for treating cancers harboring these activating mutations. ESMO Open 2017;2:e000279. However, attempts to target cancers harboring HER2 mutations have met with limited clinical success, likely due to their low frequency, incomplete understanding of the biological activity of these mutations, and the difficulty of distinguishing driver from passenger mutations. The Oncologist 24(12):e1303-e1314(2019). The role of HER2-directed therapy in these HER2-mutated cancers is an area of ​​active exploration.

[0008] Therapies targeting multiple non-redundant molecular pathways that regulate immune responses can enhance anti-tumor immunotherapy. However, not all combinations have acceptable safety and / or efficacy. There remains a need for combination therapies with acceptable safety profiles and high efficacy for the treatment of cancer, particularly for the treatment of breast cancer and cervical cancer. Therapies targeting multiple non-redundant molecular pathways that regulate immune responses can enhance anti-tumor immunotherapy. However, not all combinations have acceptable safety and / or efficacy. There remains a need for combination therapies with acceptable safety profiles and high efficacy for the treatment of cancer, particularly for the treatment of HER2+ solid tumors.

[0009] All references cited herein, including patent applications, patent publications, and scientific literature, are incorporated by reference in their entirety, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference. Summary of the Invention

[0010] Provided herein is a method of treating cancer in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death-1 (PD-1) and inhibits PD-1 activity, and tucatinib, or a salt or solvate thereof, wherein the cancer is a solid tumor. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment of pembrolizumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment of nivolumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is nivolumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is administered intravenously. In some embodiments, one or more therapeutic effects in a subject are improved compared to baseline after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof. In some embodiments, the one or more therapeutic effects are selected from the group consisting of tumor size derived from the cancer, objective response rate, duration of response, time to response, progression-free survival, and overall survival. In some embodiments, the size of a tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of a tumor derived from the cancer before administration of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof. In some embodiments, the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In some embodiments, the subject exhibits progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof. In some embodiments, the subject exhibits an overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof. In some embodiments, the duration of response to tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof. In some embodiments, the infiltration of natural killer (NK) cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of PD-1-expressing CD8+ T cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing IFNγ increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing TIM3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing OX40 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells expressing FOXP3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells that do not express FOXP3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells expressing Ki67 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the ratio of CD4+ T cells to CD8+ T cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, neutrophil infiltration is decreased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of CD11b dendritic cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II high-expressing macrophages is increased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II low-expressing macrophages is decreased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the solid tumor is a HER2+ solid tumor. In some embodiments, the cancer has been determined to express a HER2 mutant form. In some embodiments, the cancer expresses a HER2 mutant form. In some embodiments, the HER2 mutant form is determined by DNA sequencing. In some embodiments, the HER2 mutant form is determined by RNA sequencing. In some embodiments, the HER2 mutant form is determined by nucleic acid sequencing. In some embodiments, the nucleic acid sequencing is next-generation sequencing (NGS). In some embodiments, the HER2 mutant form is determined by polymerase chain reaction (PCR). In some embodiments, the HER2 mutation type is determined by analyzing a sample obtained from the subject. In some embodiments, the sample obtained from the subject is a cell-free plasma sample. In some embodiments, the sample obtained from the subject is a tumor biopsy. In some embodiments, the HER2 mutation comprises at least one amino acid substitution, insertion, or deletion compared to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the HER2 mutation is an activating mutation. In some embodiments, the HER2 mutation is a mutation in the extracellular domain, kinase domain, or transmembrane / juxtamembrane domain, or any combination thereof. In some embodiments, the HER2 mutation is a mutation in the extracellular domain selected from the group consisting of G309A, G309E, S310F, S310Y, C311R, C311S, and C334S. In some embodiments, the HER2 mutation is a mutation in the kinase domain at an amino acid residue selected from the group consisting of Y772, G776, G778, and T798. In some embodiments, the HER2 mutation is a G776 YVMA insertion. In some embodiments, the HER2 mutation is a mutation in the kinase domain selected from the group consisting of T733I, L755P, L755S, I767M, L768S, D769N, D769Y, D769H, V777L, V777M, L841V, V842I, N857S, T862A, L869R, H878Y, and R896C. In some embodiments, the HER2 mutation is a mutation in the kinase domain at amino acid residue V697. In some embodiments, the HER2 mutation is a mutation in the transmembrane / juxtamembrane domain selected from the group consisting of S653C, I655V, V659E, G660D, and R678Q. In some embodiments, the cancer does not have HER2 amplification, and the absence of HER2 amplification is determined by immunohistochemistry (IHC). In some embodiments, the cancer has a HER2 amplification score of 0 or 1+, and the HER2 amplification score is determined by immunohistochemistry (IHC). In some embodiments, the cancer has a less than 2-fold increase in HER2 protein levels. In some embodiments, the solid tumor has been determined to contain HER2 overexpression / amplification. In some embodiments, the solid tumor contains HER2 overexpression / amplification. In some embodiments, HER2 overexpression is 3+ overexpression as determined by immunohistochemistry (IHC). In some embodiments, HER2 amplification is determined by an in situ hybridization assay. In some embodiments, the in situ hybridization assay is a fluorescent in situ hybridization (FISH) assay. In some embodiments, the in situ hybridization assay is chromogenic in situ hybridization. In some embodiments, HER2 amplification is determined in tissue by next generation sequencing. In some embodiments, HER2 amplification is determined in circulating tumor DNA (ctDNA) by a blood-based next generation sequencing assay. In some embodiments, the solid tumor is a metastatic solid tumor. In some embodiments, the solid tumor is locally advanced. In some embodiments, the solid tumor is unresectable. In some embodiments, the solid tumor is selected from the group consisting of cervical cancer, uterine cancer, gallbladder cancer, bile duct cancer, urothelial cancer, lung cancer, breast cancer, gastroesophageal cancer, and colorectal cancer. In some embodiments, the breast cancer is HER2+ breast cancer. In some embodiments, the breast cancer is hormone receptor positive (HR+) breast cancer. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the solid tumor is sensitive to trastuzumab. In some embodiments, the solid tumor is resistant to trastuzumab. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to the subject at a dose of about 150 mg to about 650 mg. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to the subject at a dose of about 300 mg. In some embodiments, tucatinib, or a salt or solvate thereof, is administered once or twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to the subject at a dose of about 300 mg twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered orally to the subject. In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject to treat cancer. In some embodiments, the one or more additional therapeutic agents is an anti-CTLA4 antibody or antigen-binding fragment thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the CDRs of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is ipilimumab or a biosimilar thereof. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express CTLA4. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express PD-1. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the cancer cells from the subject express PD-L1. In some embodiments, treating the subject results in a tumor growth inhibition (TGI) index of at least about 85%. In some embodiments, treating the subject results in a TGI index of about 100%. In some embodiments, the subject has one or more adverse events, and an additional therapeutic agent is further administered to eliminate or reduce the severity of the one or more adverse events. In some embodiments, the subject is at risk of developing one or more adverse events, and an additional therapeutic agent is further administered to prevent or reduce the severity of the one or more adverse events. In some embodiments, the one or more adverse events are Grade 3 or higher. In some embodiments, the one or more adverse events are serious adverse events. In some embodiments, the subject is human. In some embodiments, tucatinib, or a salt or solvate thereof, is in a pharmaceutical composition comprising tucatinib, or a salt or solvate thereof, and a pharmaceutically acceptable carrier. In some embodiments, the anti-PD-1 antibody, or antigen-binding fragment thereof, is in a pharmaceutical composition comprising an anti-PD-1 antibody, or antigen-binding fragment thereof, and a pharmaceutically acceptable carrier. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is in a pharmaceutical composition comprising the anti-CTLA4 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier.

[0011] Also provided herein is a kit comprising tucatinib, or a salt or solvate thereof, and an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death-1 (PD-1) and inhibits PD-1 activity, and instructions for using the tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody or antigen-binding fragment thereof according to any of the embodiments herein.

[0012] Also provided herein are methods of treating cancer in a subject, the method comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to programmed death-ligand-1 (PD-L1) and inhibits PD-L1 activity, and tucatinib, or a salt or solvate thereof, wherein the cancer is a solid tumor. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, embafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment of atezolizumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the complementarity determining regions (CDRs) of the antibody or antigen-binding fragment of BMS936559. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the complementarity determining regions (CDRs) of the antibody or antigen-binding fragment of durvalumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the complementarity determining regions (CDRs) of the antibody or antigen-binding fragment of avelumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is atezolizumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is BMS-936559. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is avelumab. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is administered intravenously. In some embodiments, one or more therapeutic effects in a subject are improved compared to baseline after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof. In some embodiments, the one or more therapeutic effects are selected from the group consisting of tumor size derived from the cancer, objective response rate, duration of response, time to response, progression-free survival, and overall survival. In some embodiments, the size of a tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of a tumor derived from the cancer before administration of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof. In some embodiments, the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In some embodiments, the subject exhibits progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof. In some embodiments, the subject exhibits an overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof. In some embodiments, the duration of response to tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof. In some embodiments, the infiltration of natural killer (NK) cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of PD-1-expressing CD8+ T cells is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing IFNγ is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing TIM3 is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing OX40 is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells expressing FOXP3 is increased in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells that do not express FOXP3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells that express Ki67 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the ratio of CD4+ T cells to CD8+ T cells increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of neutrophils decreases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of CD11b dendritic cells increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II-high expressing macrophages increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II low-expressing macrophages is decreased in a solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the solid tumor is a HER2+ solid tumor. In some embodiments, the cancer has been determined to express a HER2 variant. In some embodiments, the cancer expresses a HER2 variant. In some embodiments, the HER2 variant is determined by DNA sequencing. In some embodiments, the HER2 variant is determined by RNA sequencing. In some embodiments, the HER2 variant is determined by nucleic acid sequencing. In some embodiments, the nucleic acid sequencing is next-generation sequencing (NGS). In some embodiments, the HER2 variant is determined by polymerase chain reaction (PCR). In some embodiments, the HER2 variant is determined by analyzing a sample obtained from the subject. In some embodiments, the sample obtained from the subject is a cell-free plasma sample. In some embodiments, the sample obtained from the subject is a tumor biopsy. In some embodiments, the HER2 mutation comprises at least one amino acid substitution, insertion, or deletion compared to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the HER2 mutation is an activating mutation. In some embodiments, the HER2 mutation is a mutation in the extracellular domain, kinase domain, or transmembrane / juxtamembrane domain, or any combination thereof. In some embodiments, the HER2 mutation is a mutation in the extracellular domain selected from the group consisting of G309A, G309E, S310F, S310Y, C311R, C311S, and C334S. In some embodiments, the HER2 mutation is a mutation in the kinase domain at an amino acid residue selected from the group consisting of Y772, G776, G778, and T798. In some embodiments, the HER2 mutation is a G776 YVMA insertion. In some embodiments, the HER2 mutation is a mutation in the kinase domain selected from the group consisting of T733I, L755P, L755S, I767M, L768S, D769N, D769Y, D769H, V777L, V777M, L841V, V842I, N857S, T862A, L869R, H878Y, and R896C. In some embodiments, the HER2 mutation is a mutation in the kinase domain at amino acid residue V697. In some embodiments, the HER2 mutation is a mutation in the transmembrane / juxtamembrane domain selected from the group consisting of S653C, I655V, V659E, G660D, and R678Q. In some embodiments, the cancer does not have HER2 amplification, and the absence of HER2 amplification is determined by immunohistochemistry (IHC). In some embodiments, the cancer has a HER2 amplification score of 0 or 1+, and the HER2 amplification score is determined by immunohistochemistry (IHC). In some embodiments, the cancer has a less than two-fold increase in HER2 protein levels. In some embodiments, the solid tumor has been determined to contain HER2 overexpression / amplification. In some embodiments, the solid tumor contains HER2 overexpression / amplification. In some embodiments, HER2 overexpression is 3+ overexpression as determined by immunohistochemistry (IHC). In some embodiments, HER2 amplification is determined by an in situ hybridization assay. In some embodiments, the in situ hybridization assay is a fluorescent in situ hybridization (FISH) assay. In some embodiments, the in situ hybridization assay is chromogenic in situ hybridization. In some embodiments, HER2 amplification is determined in tissue by NGS. In some embodiments, HER2 amplification is determined in circulating tumor DNA (ctDNA) by a blood-based NGS assay. In some embodiments, the solid tumor is a metastatic solid tumor. In some embodiments, the solid tumor is locally advanced. In some embodiments, the solid tumor is unresectable. In some embodiments, the solid tumor is selected from the group consisting of cervical cancer, uterine cancer, gallbladder cancer, bile duct cancer, urothelial cancer, lung cancer, breast cancer, gastroesophageal cancer, and colorectal cancer. In some embodiments, the breast cancer is HER2+ breast cancer. In some embodiments, the breast cancer is hormone receptor positive (HR+) breast cancer. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the solid tumor is sensitive to trastuzumab. In some embodiments, the solid tumor is resistant to trastuzumab. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to the subject at a dose of about 150 mg to about 650 mg. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to the subject at a dose of about 300 mg. In some embodiments, tucatinib, or a salt or solvate thereof, is administered once or twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject at a dose of about 300 mg twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered orally to a subject. In some embodiments, the method further comprises administering to the subject one or more additional therapeutic agents to treat cancer. In some embodiments, the one or more additional therapeutic agents are an anti-CTLA4 antibody or antigen-binding fragment thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the CDRs of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is ipilimumab or a biosimilar thereof. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express CTLA4. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express PD-1. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the cancer cells from the subject express PD-L1. In some embodiments, treating the subject results in a tumor growth inhibition (TGI) index of at least about 85%. In some embodiments, treating the subject results in a TGI index of about 100%. In some embodiments, the subject has one or more adverse events, and an additional therapeutic agent is further administered to eliminate or reduce the severity of the one or more adverse events. In some embodiments, the subject is at risk of developing one or more adverse events, and an additional therapeutic agent is further administered to prevent or reduce the severity of the one or more adverse events. In some embodiments, the one or more adverse events are Grade 3 or higher. In some embodiments, the one or more adverse events are serious adverse events. In some embodiments, the subject is human. In some embodiments, tucatinib, or a salt or solvate thereof, is in a pharmaceutical composition comprising tucatinib, or a salt or solvate thereof, and a pharmaceutically acceptable carrier. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is in a pharmaceutical composition comprising an anti-PD-L1 antibody or antigen-binding fragment thereof, and a pharmaceutically acceptable carrier. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is in a pharmaceutical composition comprising the anti-CTLA4 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier.

[0013] Also provided herein is a kit comprising tucatinib, or a salt or solvate thereof, and an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death ligand-1 (PD-L1) and inhibits PD-L1 activity, and instructions for using the tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody or antigen-binding fragment thereof, according to any of the embodiments herein.

[0014] It should be understood that one, some, or all of the features of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the present invention will be apparent to those skilled in the art. These and other embodiments of the present invention are further described in the detailed description that follows. [Brief explanation of the drawings]

[0015] [Figure 1] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-resistant Fo5 mouse tumor model. [Figure 2A] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2B] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2C] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2D] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2E] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2F] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2G] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2H] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2I]1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2J] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2K] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 2L] 1 is a series of graphs showing the effect of tucatinib on the tumor microenvironment using a trastuzumab-sensitive H2N113 tumor model. [Figure 3] Heatmap RNA profiles of trastuzumab-resistant Fo5 tumors treated with tucatinib or vehicle control. The IFNγ-associated gene signature is shown in A, and the extended immune signature is shown in B. [Figure 4] 1 is a series of graphs showing the effect of tucatinib and various combination treatments on Fo5 tumor growth (A) and survival (B) using the treatments indicated in the legend. N=5 / treatment group. [Figure 5] 1 shows the in vitro effect of various doses of tucatinib on cell growth of cell lines (A) BT474, (B) SKBR3, and (C) H2N113. [Figure 6] 1 shows a scheme of the H2N113 trastuzumab-sensitive HER2-positive mouse tumor model for evaluating the effect of tucatinib on tumor size and mouse survival. [Figure 7] 1 shows a scheme of the Fo5 trastuzumab-resistant HER2-positive mouse tumor model for evaluating the effect of tucatinib on tumor size and mouse survival. [Figure 8]Results of tucatinib in the H2N113 trastuzumab-sensitive HER2-positive mouse tumor model are shown. BALB / cMMTV mice inoculated with H2N113 by subcutaneous injection were treated by oral gavage with the indicated doses of tucatinib or vehicle control, and (A) tumor volume and (B) percent survival were assessed at the indicated time points. Data shown for tumor volume represent mean tumor volume (mm3) + / - SEM. P values ​​represent two-way ANOVA analysis with post-hoc Tucky's test for tumor growth; log-rank (Mantel-Cox) test for survival fraction. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. [Figure 9] Results of tucatinib in the Fo5 trastuzumab-resistant HER2-positive mouse tumor model are shown. FVB mice implanted with Fo5 tumors were treated by oral gavage with the indicated doses of tucatinib or vehicle control, and (A) tumor volume and (B) percent survival were assessed at the indicated time points. Data shown for tumor volume represent mean tumor volume (mm3) + / - SEM. P values ​​represent two-way ANOVA analysis with post-hoc Tucky's test for tumor growth; log-rank (Mantel-Cox) test for survival fraction. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. [Figure 10] Figure 1 shows validation of the Fo5 tumor model for trastuzumab resistance. FVB mice were implanted with Fo5 tumors, treated with trastuzumab or vehicle control, and then assessed for (A) tumor volume and (B) survival. [Figure 11] 1 shows inhibition of the HER2 signaling pathway after treatment with tucatinib (T) or vehicle control (V) in (A) Fo5 tumors and (B) H2N113 tumors, as assessed by Western blot. [Figure 12] A-E show the effect on the indicated cell populations at day 14 after treatment with tucatinib (T) or vehicle control (V) in H2N113 tumors, assessed by ex vivo FACS analysis and expressed as percentage abundance relative to the parental population. [Figure 13]A-B show the effect on the indicated cell populations at 14 days after treatment with tucatinib (T) or vehicle control (V) as assessed by ex vivo FACS analysis and expressed as a percentage abundance relative to the parental population. [Figure 14] The effect on NK cell populations at 14 days after treatment with tucatinib (T) or vehicle control (V) is shown, as assessed by ex vivo FACS analysis and expressed as a percentage abundance relative to the parental population. [Figure 15] A-B show PD-L1 expression in CD45+ TILs after treatment with tucatinib (T) or vehicle control (V). [Figure 16] Shown is the effect on the indicated cell populations at 10 days after treatment with tucatinib (T) or vehicle control (V) in Fo5 tumors, assessed by ex vivo FACS analysis and expressed as percentage abundance relative to the parental population. [Figure 17] 1 shows the results of ex vivo RNA extraction and gene expression analysis of Fo5 tumors treated with tucatinib compared to tumors treated with a vehicle control. Normalized enrichment scores (NES) of the indicated hallmark genes are shown. [Figure 18] AB show the results of ex vivo RNA extraction and gene expression analysis of Fo5 tumors treated with tucatinib compared to tumors treated with vehicle control. (A) Hallmark interferon-γ and (B) Hallmark interferon-α NES are shown. [Figure 19] 1 shows the results of ex vivo RNA extraction and gene expression analysis of Fo5 tumors treated with tucatinib compared to tumors treated with a vehicle control. NES for the specified gene ontology gene sets are shown. [Figure 20] A-B show the results of ex vivo RNA extraction and gene expression analysis of Fo5 tumors treated with tucatinib compared to tumors treated with vehicle control. (A) Gene Ontology NES for antigen binding and (B) Gene Ontology NES for antigen processing and presentation of exogenous peptides via MHC I are shown. [Figure 21A] 1 shows heatmap RNA profiles of Fo5 tumors treated with tucatinib or vehicle control. Gene signatures of the indicated genes are shown in terms of NES in tucatinib-treated Fo5 cells compared to vehicle control treatment. [Figure 21B] 1 shows heatmap RNA profiles of Fo5 tumors treated with tucatinib or vehicle control. Gene signatures of the indicated genes are shown in terms of NES in tucatinib-treated Fo5 cells compared to vehicle control treatment. [Figure 21C] 1 shows heatmap RNA profiles of Fo5 tumors treated with tucatinib or vehicle control. Gene signatures of the indicated genes are shown in terms of NES in tucatinib-treated Fo5 cells compared to vehicle control treatment. [Figure 21D] 1 shows heatmap RNA profiles of Fo5 tumors treated with tucatinib or vehicle control. Gene signatures of the indicated genes are shown in terms of NES in tucatinib-treated Fo5 cells compared to vehicle control treatment. [Figure 22] Figure 1 shows the effect of treatment with tucatinib alone or in combination with anti-PD-L1 in the H2N113 mouse model, as assessed by (A) tumor volume and (B) survival. Tumor volume data shown represent mean tumor volume (mm3) + / - SEM. Groups are representative of two replicates (n = 4-8 / group). P values ​​represent two-way ANOVA analysis with post-hoc Tucky's test for tumor growth and log-rank (Mantel-Cox) test for survival. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. [Figure 23]The effects of tucatinib treatment alone or in combination with anti-PD-1 in the Fo5 mouse model are shown, as assessed by (A) tumor volume and (B) survival. Tumor volume data shown represent mean tumor volume (mm3) + / - SEM. Groups are representative of two replicates (n = 4-8 / group). P values ​​represent two-way ANOVA analysis with post-hoc Tucky's test for tumor growth and log-rank (Mantel-Cox) test for survival. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. [Figure 24] The effects of tucatinib alone or in combination with trastuzumab treatment in the Fo5 mouse model are shown, as assessed by (A) tumor volume and (B) survival. Tumor volume data shown represent the mean tumor volume (mm) + / - SEM. Groups are representative of two replicates (n = 4-8 / group). P values ​​represent two-way ANOVA analysis with post-hoc Tucky's test for tumor growth and log-rank (Mantel-Cox) test for survival. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. DETAILED DESCRIPTION OF THE INVENTION

[0016] I. Definition So that this disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise specified herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout this application.

[0017] As used herein, the terms "a," "an," or "the" include not only aspects with one member, but also aspects with more than one member. For example, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "cell" includes a plurality of such cells, a reference to an "agent" includes one or more agents known to those of skill in the art, and so forth.

[0018] The term "or" as used herein is generally intended to be interpreted non-exclusively. For example, a claim that reads "A composition comprising A or B" would typically present an embodiment with a composition that includes both A and B. However, "or" should be interpreted to exclude consistent combinations within the presented embodiment (e.g., a composition with a pH of 9-10 or a pH of 7-8).

[0019] The group "A or B" is typically equivalent to the group "selected from the group consisting of A and B."

[0020] As used herein, the term "and / or" shall be deemed to indicate that each of the two specified features or components is specifically disclosed, regardless of the presence or absence of the other. Thus, the term "and / or" used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0021] It is to be understood that aspects and embodiments of the invention described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.

[0022] As used herein, the terms "about" and "approximately" generally refer to an acceptable degree of error for a measured quantity given the nature or precision of the measurement. Typical examples of degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Any reference to "about X" specifically refers to at least the values ​​X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Thus, "about X" is intended to teach and provide specification support for a claim limitation, for example, "0.98X." The terms "about" and "approximately," when specifically referring to a given amount, encompass and describe the given amount itself.

[0023] Alternatively, in biological systems, the terms "about" and "approximately" can refer to values ​​that are within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold of a given value. Numerical quantities set forth herein are approximations unless otherwise indicated, meaning that the term "about" or "approximately" can be assumed even when not expressly stated.

[0024] When "about" is applied to the beginning of a numerical range, it applies to both ends of that range. Thus, "about 5-20%" is equivalent to "about 5% to about 20%." When "about" is applied to the first value in a group of values, it applies to all values ​​in that group. Thus, "about 7, 9, or 11 mg / kg" is equivalent to "about 7, about 9, or about 11 mg / kg."

[0025] As used herein, the term "comprising" should generally be interpreted as not excluding additional components. For example, a claim "a composition comprising A" would encompass compositions containing A and B; A, B, and C; A, B, C, and D; A, B, C, D, and E, etc.

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.

[0027] Units, prefixes, and symbols are shown in the form accepted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. The headings provided herein are not limiting of various aspects of the disclosure, which may be understood by reference to the specification in its entirety. Accordingly, the terms defined below are more fully defined by reference to the specification in its entirety.

[0028] As used herein, the term "co-administration" includes sequential or simultaneous administration of two or more structurally distinct compounds. For example, two or more structurally distinct pharmaceutically active compounds can be co-administered by administering a pharmaceutical composition adapted for oral administration containing two or more structurally distinct active pharmaceutically active compounds. As another example, two or more structurally distinct compounds can be co-administered by administering one compound followed by the other compound. Two or more structurally distinct compounds can include an anti-PD-1 antibody and tucatinib. In some cases, co-administered compounds are administered by the same route. In other cases, co-administered compounds are administered via different routes. For example, one compound can be administered orally, and the other compound can be administered sequentially or simultaneously, for example, by intravenous, intramuscular, subcutaneous, or intraperitoneal injection. Co-administered or sequentially administered compounds or compositions can be administered such that the anti-PD-1 antibody and tucatinib are simultaneously present in a subject or cell at effective concentrations. The co-administered or sequentially administered compounds or compositions can be administered such that effective concentrations of the anti-PD-L1 antibody and tucatinib are simultaneously present in a subject or cell.

[0029] "Cancer" refers to a broad group of diseases characterized by the uncontrolled growth of abnormal cells in the body. "Cancer" or "cancerous tissue" can include tumors. Uncontrolled cell division and growth can lead to the formation of malignant tumors that invade nearby tissues and may metastasize to distant parts of the body via the lymphatic system or bloodstream. After metastasis, a distant tumor can be said to "originate" from the pre-metastatic tumor. For example, a "tumor originating from" breast cancer refers to a tumor that is the result of breast cancer metastasis.

[0030] In the context of cancer, the term "stage" refers to a classification of the extent of cancer. Factors considered when staging cancer include, but are not limited to, tumor size, tumor invasion into nearby tissues, and whether the tumor has metastasized to other sites. The specific criteria and parameters for identifying the stage may vary depending on the type of cancer. Cancer staging is used, for example, to help determine prognosis or identify the most appropriate treatment option(s).

[0031] One non-limiting example of a cancer staging system is called the "TNM" system. In the TNM system, "T" refers to the size and spread of the main tumor, "N" refers to the number of nearby lymph nodes to which the cancer has spread, and "M" refers to whether the cancer has metastasized. "TX" indicates that the main tumor cannot be measured, "T0" indicates that the main tumor is not visible, and "T1," "T2," "T3," and "T4" indicate the size or spread of the main tumor, with higher numbers indicating larger tumors or tumors that have grown into nearby tissues. "NX" indicates that cancer in nearby lymph nodes cannot be measured, "N0" indicates that there is no cancer in nearby lymph nodes, and "N1," "N2," "N3," and "N4" indicate the number and location of lymph nodes to which the cancer has spread, with higher numbers indicating more lymph nodes containing cancer. "MX" indicates that metastasis cannot be measured, "M0" indicates that metastasis has not occurred, and "M1" indicates that the cancer has metastasized to other parts of the body.

[0032] As another non-limiting example of a cancer staging system, cancers are classified or graded as having one of five stages: "Stage 0," "Stage I," "Stage II," "Stage III," or "Stage IV." Stage 0 indicates that abnormal cells are present but have not spread to nearby tissues. This is also commonly referred to as intraepithelial neoplasia (CIS). CIS is not cancer, but may subsequently progress to cancer. Stages I, II, and III indicate the presence of cancer. Higher numbers indicate larger tumor size or tumor spread to nearby tissues. Stage IV indicates the cancer has metastasized. Those skilled in the art will be familiar with various cancer staging systems and will be able to apply or interpret them easily.

[0033] The term "HER2" (also known as HER2 / neu, ERBB2, CD340, receptor tyrosine protein kinase erbB-2, proto-oncogene Neu, and human epidermal growth factor receptor 2) refers to a member of the human epidermal growth factor receptor (HER / EGFR / ERBB) family of receptor tyrosine kinases. Amplification or overexpression of HER2 plays an important role in the development and progression of certain aggressive types of cancer, including colorectal cancer, gastric cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC)), biliary tract cancer (e.g., cholangiocarcinoma, gallbladder cancer), bladder cancer, esophageal cancer, melanoma, ovarian cancer, liver cancer, prostate cancer, pancreatic cancer, small intestine cancer, head and neck cancer, uterine cancer, cervical cancer, and breast cancer. Non-limiting examples of HER2 nucleotide sequences are set forth in GenBank Reference Nos. NP_001005862, NP_001289936, NP_001289937, NP_001289938, and NP_004448. Non-limiting examples of HER2 peptide sequences are set forth in GenBank Reference Nos. NP_001005862, NP_001276865, NP_001276866, NP_001276867, and NP_004439.

[0034] If HER2 is amplified or overexpressed within or on a cell, the cell is said to be "HER2 positive." The level of HER2 amplification or overexpression in HER2-positive cells is generally expressed as a score ranging from 0 to 3 (i.e., HER2 0, HER2 1+, HER2 2+, or HER2 3+), with higher scores indicating greater expression. Mol Biol Int. 2014:852748 (2014). Scoring methods can be based on cell membrane staining patterns determined by immunohistochemistry, as follows: i.3+: positive HER2 expression with homogeneous and intense membrane staining in more than 30% of invasive tumor cells; ii.2+: HER2 protein expression is borderline, heterogeneous or weakly intense, but complete membrane staining with circumferential distribution in at least 10% of cells; iii.0 or 1+: HER2 protein expression is negative.

[0035] The term "tucatinib," also known as ONT-380 and ARRY-380, refers to a small molecule tyrosine kinase inhibitor that suppresses or blocks HER2 activation. Tucatinib has the following structure: [ka]

[0036] The term "immunoglobulin" refers to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) chains and one pair of heavy (H) chains, all four interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)). Briefly, each heavy chain typically comprises a heavy chain variable region (referred to herein as V H or VH) and heavy chain constant region (C H or CH). The heavy chain constant region typically comprises C H 1. C H2, and C H The heavy chains generally comprise three domains: a light chain variable region (VL) and a light chain variable region (VV). The heavy chains are generally interconnected via disulfide bonds at the so-called "hinge region". Each light chain typically comprises a light chain variable region (VL) and a light chain variable region (VV). L or VL) and a light chain constant region (C L The light chain constant region typically comprises C L The CL may be of the κ (kappa) or λ (lambda) isotype. The terms "constant domain" and "constant region" are used interchangeably herein. Immunoglobulins may be derived from any of the commonly known isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. IgG subclasses are also well known to those skilled in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. "Isotype" refers to the antibody class or subclass (e.g., IgM or IgG1) encoded by the heavy chain constant region genes.

[0037] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable regions of the heavy and light chains of a native antibody (V H and V L) can be further divided into hypervariable regions, also called complementarity-determining regions (CDRs) (i.e., hypervariable regions in which the sequence and / or configuration of structurally defined loops may be hypervariable), and highly conserved regions, called framework regions (FRs), interspersed therebetween. The terms "complementarity-determining region" and "CDR," which are synonymous with "hypervariable region" or "HVR," are known in the art to refer to non-contiguous sequences of amino acids within an antibody variable region that confer antigen specificity and / or binding affinity. Generally, there are three CDRs (CDR-H1, CDR-H2, CDR-H3) in each heavy chain variable region and three CDRs (CDR-L1, CDR-L2, CDR-L3) in each light chain variable region. The terms "framework region" and "FR" are known in the art to refer to the portions of heavy and light chain variable regions other than the CDRs. Generally, there are four FRs (FR-H1, FR-H2, FR-H3, and FR-H4) in each full-length heavy chain variable region, and four FRs (FR-L1, FR-L2, FR-L3, and FR-L4) in each full-length light chain variable region. H and V L Within the CDR, there are typically three CDRs and four FRs arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mot. Biol., 195, 901-917 (1987)).

[0038] The term "antibody" (Ab) in the context of the present invention refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of either, that has the ability to specifically bind to an antigen under typical physiological conditions and has a half-life of a significant period, such as at least about 30 minutes, at least about 45 minutes, at least about 1 hour (h), at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours (h), about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 days or more, or any other relevant functionally defined period (a period sufficient to induce, promote, enhance, and / or modulate a physiological response associated with antibody binding to an antigen and / or a period sufficient for the antibody to mobilize effector activity). The variable regions of the heavy and light chains of an immunoglobulin molecule contain the binding domains that interact with the antigen. The constant region of an antibody (Ab) can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and components of the complement system, such as C1q, the first component of the classical complement system for complement activation. Antibodies may also be bispecific antibodies, diabodies, multispecific antibodies, or similar molecules.

[0039] As used herein, the term "monoclonal antibody" refers to a preparation of recombinantly produced antibody molecules with a single primary amino acid sequence. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Accordingly, the term "human monoclonal antibody" refers to an antibody displaying a single binding specificity which has variable and constant regions derived from human germline immunoglobulin sequences. Human monoclonal antibodies can be produced by hybridomas obtained by fusing B cells obtained from a transgenic or transchromosomal non-human animal, such as a transgenic mouse whose genome contains human heavy chain and light chain transgenes, with an immortalized cell.

[0040] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds PD-1 is substantially free of antibodies that specifically bind antigens other than PD-1; an isolated antibody that specifically binds PD-L1 is substantially free of antibodies that specifically bind antigens other than PD-L1). However, an isolated antibody that specifically binds PD-1 may have cross-reactivity to other antigens, such as PD-1 molecules from different species. Furthermore, an isolated antibody may be substantially free of other cellular material and / or chemicals. However, an isolated antibody that specifically binds PD-L1 may have cross-reactivity to other antigens, such as PD-L1 molecules from different species. Furthermore, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0041] A "human antibody" (HuMAb) refers to an antibody having variable regions in which both the FRs and CDRs are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region may also be derived from human germline immunoglobulin sequences. The human antibodies of the present disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human antibody" and "fully human antibody" are used interchangeably.

[0042] As used herein, the term "humanized antibody" refers to a genetically engineered non-human antibody containing a human antibody constant domain and a non-human variable domain that has been modified to contain a high level of sequence homology to the human variable domain. This can be achieved by grafting the six non-human antibody complementarity-determining regions (CDRs), which together form the antigen-binding site, onto homologous human acceptor framework regions (FRs) (see WO 92 / 22653 and EP 0 629 240). Substitution of framework residues from the parent antibody (i.e., non-human antibody) with human framework regions (back mutations) may be necessary to fully reproduce the binding affinity and specificity of the parent antibody. Structural homology modeling can be helpful in identifying amino acid residues in the framework regions that are important for the binding properties of the antibody. Thus, a humanized antibody may contain non-human CDR sequences, primarily human framework regions (optionally containing one or more amino acid back mutations to non-human amino acid sequences), and a fully human constant region. Optionally, additional amino acid modifications, not necessarily back mutations, may be applied to obtain a humanized antibody with favorable characteristics, such as affinity and biochemical properties.

[0043] The term "chimeric antibody" as used herein refers to an antibody whose variable region originates from a non-human species (e.g., rodent) and whose constant region originates from a different species, such as human. Chimeric antibodies can be produced by antibody engineering. "Antibody engineering" is a general term used to refer to various types of antibody modifications and is a process well known to those skilled in the art. In particular, chimeric antibodies can be produced using standard DNA techniques, such as those described in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, Ch. 15. Thus, chimeric antibodies can be genetically or enzymatically engineered recombinant antibodies. The production of chimeric antibodies is within the knowledge of those skilled in the art, and therefore, the production of chimeric antibodies according to the present invention may be performed by methods other than those described herein. Chimeric monoclonal antibodies for therapeutic use have been developed to reduce antibody immunogenicity. They typically contain non-human (e.g., murine) variable regions specific for an antigen of interest and human antibody heavy and light chain constant domains. The term "variable region" or "variable domain" as used in the context of a chimeric antibody refers to the region comprising the CDR and framework regions of both the heavy and light chains of an immunoglobulin.

[0044] An "anti-antigen antibody" refers to an antibody that binds to an antigen. For example, an anti-PD-1 antibody is an antibody that binds to the PD-1 antigen, an anti-PD-L1 antibody is an antibody that binds to the PD-L1 antigen, and an anti-CTLA4 antibody is an antibody that binds to the CTLA4 antigen.

[0045] An "antigen-binding portion" or "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to the antigen bound by the whole antibody. Examples of antibody fragments (e.g., antigen-binding fragments) include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. Papain digestion of an antibody produces two identical antigen-binding fragments called "Fab" fragments, each containing a single antigen-binding site, and a remaining "Fc" fragment, a name reflecting its ability to readily crystallize. Pepsin treatment yields an F(ab')2 fragment that has two antigen-binding sites and is still capable of cross-linking antigen.

[0046] "Percent sequence identity (%)" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment across the entire length of the sequences being compared. For example, the percent amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (alternatively, it can be expressed as a given amino acid sequence A having or containing a certain percent amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y where X is the number of amino acid residues at which the program scores a perfect match in an alignment of A and B, and Y is the total number of amino acid residues in B. It is understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A.

[0047] As used herein, the terms "binding," "bind," or "specifically bind" in the context of binding of an antibody to a predetermined antigen typically refer to a specific binding activity of about 10, as determined, for example, by biolayer interferometry (BLI) techniques on an Octet HTX instrument using the antibody as the ligand and the antigen as the analyte. -6 M or less, e.g., 10 -7 M or less, e.g., about 10 -8 M or less, e.g., about 10 -9 M or less, about 10 -10 M or less, or about 10 -11 M or lower K D and the antibody binds with an affinity corresponding to a K of binding to a nonspecific antigen other than the predetermined antigen or a closely related antigen (e.g., BSA, casein). D at least 10 times lower, e.g., at least 100 times lower, e.g., at least 1,000 times lower, e.g., at least 10,000 times lower, e.g., at least 100,000 times lower, D The binding affinity of the antibody is determined by the affinity of the antibody. D The amount at which the K of the antibody is lower D Because it depends on the antibody's K D If the K of binding to the antigen is very low (i.e., the antibody is highly specific), D is the K of binding to nonspecific antigens D The amount can be at least 10,000 times lower.

[0048] "K DThe term "(M)" as used herein refers to the equilibrium dissociation constant of a particular antibody-antigen interaction. Affinity and K D are inversely correlated, i.e., the higher the affinity, the higher the K D The lower the affinity, the lower the K D is intended to refer to a high

[0049] "Programmed death-1" (PD-1) refers to an immunosuppressive receptor belonging to the CD28 family. PD-1 is expressed primarily on activated T cells in vivo and binds to two ligands, PD-L1 and PD-L2. As used herein, the term "PD-1" includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, as well as analogs that share at least one epitope with hPD-1. In some embodiments, hPD-1 comprises the amino acid sequence found in GenBank Accession No. U64863.

[0050] "Programmed death-ligand-1" (PD-L1) is one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1. As used herein, the term "PD-L1" includes human PD-L1 (hPD-L1), variants, isoforms, and species homologs of hPD-L1, and analogs that share at least one epitope with hPD-L1. In some embodiments, hPD-L1 comprises the amino acid sequence found in GenBank Accession No. Q9NZQ7.

[0051] "Treatment" or "therapy" of a subject refers to any type of intervention or process performed on a subject, or the administration of an active agent to a subject, for the purpose of reversing, mitigating, ameliorating, suppressing, slowing, or preventing the onset, progression, development, severity, or recurrence of symptoms, complications, conditions, or biochemical indicators associated with a disease. In some embodiments, the disease is cancer.

[0052] A "subject" includes any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human. The terms "subject," "patient," and "individual" are used interchangeably herein.

[0053] An "effective amount" or "therapeutically effective amount" or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of drug that, when used alone or in combination with another therapeutic agent, protects a subject from developing a disease or promotes regression of the disease as indicated by a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or prevention of functional or disability impairment due to disease morbidity. The ability of a therapeutic agent to promote regression of a disease can be assessed using a variety of methods known to those skilled in the art, such as by assessing the activity of the agent in human subjects in clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0054] By way of example for the treatment of tumors, a therapeutically effective amount of an anti-cancer agent inhibits cell growth or tumor growth in a treated subject(s) (e.g., one or more treated subjects) by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% compared to an untreated subject(s) (e.g., one or more untreated subjects). In some embodiments, a therapeutically effective amount of an anti-cancer agent inhibits cell growth or tumor growth in a treated subject(s) (e.g., one or more treated subjects) by 100% compared to an untreated subject(s) (e.g., one or more untreated subjects).

[0055] In other embodiments of the present disclosure, tumor regression may be observed and sustained for a period of at least about 20 days, at least about 30 days, at least about 40 days, at least about 50 days, or at least about 60 days. Regardless of these ultimate measures of therapeutic efficacy, evaluation of immunotherapeutics must consider the "immune-related response pattern."

[0056] A therapeutically effective amount of a drug (e.g., tucatinib or a salt or solvate thereof, an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA4 antibody) includes a "prophylactically effective amount," which is any amount of drug that inhibits the development or recurrence of cancer when used alone or in combination with an anti-cancer agent in a subject at risk of developing cancer (e.g., a subject with a precancerous condition) or a subject at risk of cancer recurrence. In some embodiments, a prophylactically effective amount completely prevents the development or recurrence of cancer. "Inhibiting" the development or recurrence of cancer means either lowering the likelihood of cancer development or recurrence, or completely preventing the development or recurrence of cancer.

[0057] As used herein, a "sub-therapeutic dose" means a dose of a therapeutic compound (e.g., tucatinib or a salt or solvate thereof, an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA4 antibody) that is less than the usual or typical dose of the therapeutic compound when administered alone to treat a hyperproliferative disease (e.g., cancer).

[0058] The term "tumor growth inhibition (TGI) index" refers to a value used to describe the degree to which a drug (e.g., tucatinib, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, or a combination thereof) inhibits tumor growth compared to an untreated control. The TGI index is calculated for a specific time point (e.g., a specific day in an experiment or clinical trial) according to the following formula:

number

[0059] As used herein, the terms "synergistic" or "synergistic effect" refer to the result observed when the administration of a combination of components or agents (e.g., a combination of tucatinib and an anti-PD-1 antibody, a combination of tucatinib and an anti-PD-L1 antibody, a combination of tucatinib and an anti-CTLA4 antibody, a combination of tucatinib, an anti-PD-1 antibody, and an anti-CTLA4 antibody, or a combination of tucatinib, an anti-PD-L1 antibody, and an anti-CTLA4 antibody) produces an effect (e.g., inhibition of tumor growth, extended survival) that is greater than that expected based on the additive properties or effects of the individual components. In some embodiments, synergy is determined by performing a Bliss analysis (see, e.g., Foucquier et al. Pharmacol. Res. Perspect. (2015) 3(3):e00149; incorporated herein by reference in its entirety for all purposes). The Bliss independence model assumes that drug effects are the result of a stochastic process, and that drugs act completely independently (i.e., drugs do not interfere with each other (e.g., drugs have different sites of action), but each contributes to a common outcome). According to the Bliss independence model, the predicted effect of a combination of two drugs is calculated using the following formula: E AB =E A +E B -E A ×EB In the formula, E A and E B represent the effects of drugs A and B, respectively, and E AB represents the effect of the combination of drugs A and B. The observed effect of the combination is the predicted effect E AB The combination of two drugs is considered synergistic if the observed effect of the combination is greater than E AB The effect of the combination of two drugs is considered to be additive if the observed effect of the combination is equal to E AB If it is less, the combination of the two drugs is considered to be antagonistic.

[0060] The observed effect of a drug combination can be based, for example, on the TGI index of a subject or a population of subjects, tumor size (e.g., volume, mass), absolute change in tumor size (e.g., volume, mass) between two or more time points (e.g., from the first day treatment is administered to a specific number of days after treatment is first administered), the rate of change in tumor size (e.g., volume, mass) between two or more time points (e.g., from the first day treatment is administered to a specific number of days after treatment is first administered), or survival time. When the TGI index is used as a measure of the observed effect of a drug combination, the TGI index can be determined at one or more time points. When the TGI index is determined at two or more time points, the mean or median of multiple TGI indexes can be used as a measure of the observed effect, in some cases. Furthermore, the TGI index can be determined for a single subject or a population of subjects. When the TGI index is determined for a population, the mean or median TGI index of the population (e.g., at one or more time points) can be used as a measure of the observed effect. When tumor size or tumor growth rate is used as the measure of observed effect, tumor size or tumor growth rate can be measured in a subject or a group of subjects.In some cases, the mean or median value of tumor size or tumor growth rate is determined at two or more time points for a subject, or at one or more time points for a group of subjects.When survival time is measured in a group, the mean or median value of survival time can be used as the measure of observed effect.

[0061] Predicted combined effect E AB can be calculated using either single or multiple doses of the drugs that make up the combination (e.g., tucatinib and an anti-PD-1 antibody, tucatinib and an anti-PD-L1 antibody, or tucatinib and an anti-CTLA4 antibody). In some embodiments, the predicted combination effect E AB is calculated using only a single dose of each drug A and B (e.g., tucatinib and anti-PD-1 antibody or tucatinib and anti-PD-L1 antibody), and E A and E BThe values ​​of E are based on the effect observed with each drug when administered as a single agent. A and E B If the value of is based on the observed effects of administering drugs A and B as single agents, then E A and E B can be based, for example, on the TGI index of a subject or population of subjects in each treatment group, tumor size (e.g., volume, mass) measured at one or more time points, the absolute change in tumor size (e.g., volume, mass) between two or more time points (e.g., from the first day treatment is administered to a particular number of days after treatment is first administered), the rate of change in tumor size (e.g., volume, mass) between two or more time points (e.g., from the first day treatment is administered to a particular number of days after treatment is first administered), or survival time.

[0062] When the TGI index is used as a measure of the observed effect, the TGI index can be determined at one or more time points. When the TGI index is determined at two or more time points, the mean or median value can be used as a measure of the observed effect in some cases. Furthermore, the TGI index can be determined for a single subject or a population of subjects in each treatment group. When the TGI index is determined for a population of subjects, the mean or median TGI index of each population (e.g., at one or more time points) can be used as a measure of the observed effect. When tumor size or tumor growth rate is used as a measure of the observed effect, the tumor size or tumor growth rate can be measured for a subject or a population of subjects in each treatment group. In some cases, the mean or median tumor size or tumor growth rate is determined at two or more time points for a subject, or at one or more time points for a population of subjects. When survival time is measured for a population, the mean or median survival time can be used as a measure of the observed effect.

[0063] In some embodiments, the predicted combined effect E ABis calculated using a range of doses (i.e., the effect of each drug when administered as a single agent is observed at multiple doses, and the effects observed at multiple doses are used to determine the expected combination effect at a particular dose). AB is calculated according to the following formula: A and E B can be calculated using the value of:

number

[0064] In some embodiments, a combination of two or more drugs is considered synergistic if the combination results in an observed TGI index that is greater than the TGI index expected for the drug combination (e.g., where the expected TGI index is based on the assumption that the drugs result in an additive combination effect). In some cases, a combination is considered synergistic if the observed TGI index is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% greater than the TGI index expected for the drug combination.

[0065] In some embodiments, tumor growth rate (e.g., rate of change in tumor size (e.g., volume, mass)) is used to determine whether a drug combination is synergistic (e.g., if the tumor growth rate is slower than expected if the drug combination produces an additive effect, the drug combination is synergistic). In other embodiments, survival time is used to determine whether a drug combination is synergistic (e.g., if the survival time of a subject or population of subjects is longer than expected if the drug combination produces an additive effect, the drug combination is synergistic).

[0066] "Immune-related response pattern" refers to a clinical response pattern often observed in cancer patients treated with immunotherapeutic agents that exert antitumor effects by inducing cancer-specific immune responses or by modifying innate immune processes. This response pattern is characterized by a beneficial therapeutic effect following an initial increase in tumor burden or the appearance of new lesions, which, in the evaluation of conventional chemotherapeutic agents, would be classified as disease progression and is synonymous with drug failure. Therefore, proper evaluation of immunotherapeutic agents may require longitudinal monitoring of the effects of these agents on the target disease.

[0067] By way of example, an "anti-cancer drug" promotes cancer regression in a subject. In some embodiments, a therapeutically effective amount of a drug promotes cancer regression to the point of eliminating the cancer. "Promoting cancer regression" means that administration of an effective amount of a drug, alone or in combination with an anti-cancer drug, results in a decrease in tumor growth or size, tumor necrosis, a reduction in the severity of at least one disease symptom, an increase in the frequency and duration of disease symptom-free periods, or prevention of functional impairment or disability due to disease morbidity. Additionally, the terms "effective" and "efficacy" with respect to treatment include both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of a drug to promote cancer regression in a patient. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse effects) at the cellular, organ, and / or organismal level resulting from administration of the drug.

[0068] A "durable response" refers to a sustained reduction in tumor growth after treatment has ended. For example, tumor size may remain the same or smaller compared to the size at the beginning of the administration period. In some embodiments, the sustained response lasts for at least the same duration as the treatment period, or at least 1.5, 2.0, 2.5, or 3 times the treatment period.

[0069] As used herein, "complete response" or "CR" refers to the disappearance of all target lesions, "partial response" or "PR" refers to at least a 30% reduction in the sum of the longest diameters (SLD) of target lesions, based on baseline SLD, and "stable disease" or "SD" refers to failure to achieve sufficient reduction in target lesions to meet the requirements for PR and failure to achieve sufficient growth to meet the requirements for PD, based on the smallest SLD since the start of treatment.

[0070] As used herein, "progression-free survival" or "PFS" refers to the length of time during and after treatment during which the disease being treated (e.g., cancer) does not worsen. Progression-free survival can include the amount of time a patient experiences a complete or partial response, as well as the amount of time a patient experiences stable disease.

[0071] As used herein, "overall response rate" or "ORR" refers to the sum of the complete response (CR) rate and the partial response (PR) rate.

[0072] As used herein, "overall survival" or "OS" refers to the proportion of individuals in a group who are likely to be alive after a particular period of time.

[0073] The term "body weight-based dose" as used herein means that the dose administered to a subject is calculated based on the subject's body weight. For example, if a subject weighing 60 kg requires 2.0 mg / kg of anti-PD-1 antibody, the appropriate amount of anti-PD-1 antibody to administer to the subject can be calculated and used (i.e., 120 mg).

[0074] The use of the term "fixed dose" in connection with the methods of the present disclosure means that two or more different agents (e.g., tucatinib, or a salt or solvate thereof, and an anti-PD-1 antibody) are administered to a subject in a specific (fixed) ratio to one another. In some embodiments, the fixed dose is based on the amount (e.g., mg) of tucatinib, or a salt or solvate thereof, or antibody. In certain embodiments, the fixed dose is based on the concentration (e.g., mg / ml) of tucatinib, or a salt or solvate thereof, or antibody. For example, administering an anti-PD-1 antibody and tucatinib, or a salt or solvate thereof, in a 3:1 ratio to a subject may mean that about 240 mg of the anti-PD-1 antibody and about 80 mg of tucatinib, or a salt or solvate thereof, or about 3 mg / ml of the anti-PD-1 antibody and about 1 mg / ml of tucatinib, or a salt or solvate thereof, are administered to the subject.

[0075] The use of the term "fixed dose" with respect to the methods and dosages disclosed herein refers to a dose administered to a subject without regard to the subject's body weight or body surface area (BSA). Thus, a fixed dose is provided as an absolute amount of agent (e.g., tucatinib, or a salt or solvate thereof, and / or an anti-PD-1 antibody) rather than as a mg / kg dose. For example, a subject weighing 60 kg and a subject weighing 100 kg would receive the same dose of tucatinib, or a salt or solvate thereof, or antibody (e.g., 300 mg of tucatinib, or a salt or solvate thereof, or, for example, 240 mg of an anti-PD-1 antibody).

[0076] The term "pharmaceutically acceptable" indicates that the substance or composition must be chemically and / or toxicologically compatible with other ingredients contained in the formulation and / or the mammal being treated.

[0077] As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 4,4'-methylene-bis-(2-hydroxy-3-naphthoate)) salts, alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt may include the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. In instances where multiple charged atoms are part of the pharmaceutically acceptable salt, it may have multiple counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.

[0078] "Administering" or "administration" refers to the physical introduction of a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those of skill in the art. Exemplary routes of administration for tucatinib or a salt or solvate thereof, and / or an anti-PD-1 antibody and / or an anti-PD-L1 antibody and / or an anti-CTLA4 antibody include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, such as by injection or infusion (e.g., intravenous infusion). As used herein, the term "parenteral administration" refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intrathecal, epidural, and intrasternal injection and infusion, and in vivo electroporation. Therapeutic agents can be administered via non-parenteral routes, i.e., oral. Other non-parenteral routes include topical, epidermal, or mucosal routes of administration, such as intranasal, vaginal, rectal, sublingual, or topical routes of administration. Administration can also be, for example, single, multiple, and / or over one or more extended periods of time.

[0079] The terms "baseline" or "baseline value," as used interchangeably herein, may refer to the measurement or characterization of symptoms prior to or at the start of a therapy (e.g., tucatinib or a salt or solvate thereof described herein and / or an anti-PD-1 antibody described herein and / or an anti-PD-L1 antibody described herein). The baseline value can be compared to a reference value to determine the reduction or improvement in symptoms of tucatinib or a salt or solvate thereof contemplated herein, and / or a PD-1- and / or PD-L1-associated disease (e.g., a solid tumor). The terms "reference" or "reference value," as used interchangeably herein, may refer to the measurement or characterization of symptoms following the administration of a therapy (e.g., tucatinib or a salt or solvate thereof described herein and / or an anti-PD-1 antibody described herein and / or an anti-PD-L1 antibody described herein). The reference value can be measured one or more times during a dosing regimen or treatment cycle or at the end of a dosing regimen or treatment cycle. A "reference value" can be an absolute value; a relative value; a value with upper and / or lower limits; a range of values; an average value; a median value; or a value compared to a baseline value.

[0080] Similarly, a "baseline value" can be an absolute value; a relative value; a value with upper and / or lower limits; a range of values; an average value; a median value; or a value compared to a reference value. Reference and / or baseline values ​​can be obtained from one individual, two different individuals, or a group of individuals (e.g., a group of 2, 3, 4, 5, or more individuals).

[0081] As used herein, the term "monotherapy" means that tucatinib or a salt or solvate thereof, an anti-PD-1 antibody, or an anti-PD-L1 antibody is the only anti-cancer agent administered to a subject during a treatment cycle. However, other therapeutic agents may also be administered to a subject. For example, anti-inflammatory drugs or other agents administered to cancer subjects to treat symptoms associated with cancer (e.g., inflammation, pain, weight loss, and general fatigue) other than the underlying cancer itself may be administered during monotherapy.

[0082] As used herein, an "adverse event" (AE) is any unfavorable, generally unintended, or undesirable sign (including abnormal laboratory findings), symptom, or disease associated with the use of a medical treatment. A medical treatment may have one or more associated AEs, and each AE may be of the same or different severity. Reference to a method that can "alter an adverse event" refers to a treatment regimen that reduces the occurrence and / or severity of one or more AEs associated with the use of a different treatment regimen.

[0083] As used herein, a "serious adverse event" or "SAE" is an adverse event that meets one of the following criteria: Fatal or life-threatening (as used in the definition of serious adverse events, "life-threatening" refers to an event that is at risk of causing death to the patient at the time of the event, not an event that, if more severe, might have resulted in death. Permanent or significant impairment / disability ·Congenital anomalies / congenital defects Medically significant, defined as an event that endangers the patient or that may require medical or surgical intervention to prevent one of the outcomes listed above. Determining whether an AE is "medically significant" requires the exercise of medical and scientific judgment. Anything that requires an extension of an inpatient's hospital stay or an existing hospital stay, excluding: 1) routine treatment or monitoring of an underlying disease without any deterioration of the condition; 2) elective or pre-planned treatment of a pre-existing condition that is unrelated to the indication under study and that has not worsened since the signed informed consent; and 3) social reasons and respite care without any deterioration of the patient's general condition.

[0084] The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite article "a" or "an" should be understood to refer to "one or more" of any elements being cited or listed.

[0085] The terms "about" or "essentially comprising" refer to a value or composition that is within an acceptable error range for a particular value or composition, as determined by one of ordinary skill in the art, and depend, in part, on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "essentially comprising" can mean within 1 or more than 1 standard deviation, as practiced in the art. Alternatively, "about" or "essentially comprising" can mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, the term can mean up to an order of magnitude or up to 5 times the value. When a particular value or composition is described in this application and claims, unless otherwise indicated, the meaning of "about" or "essentially comprising" should be assumed to be within an acceptable error range for that particular value or composition.

[0086] As used herein, the terms "about once every week," "about once every two weeks," or any other similar administration interval term refer to approximate numbers. "About once every week" can include every 7 days ± 1 day, i.e., every 6 to 8 days. "About once every two weeks" can include every 14 days ± 2 days, i.e., every 12 to 16 days. "About once every three weeks" can include every 21 days ± 3 days, i.e., every 18 to 24 days. Similar approximations apply to, for example, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, and about once every 12 weeks. In some embodiments, an administration interval of about once every 6 weeks or about once every 12 weeks means that the first administration can be administered on any day in week 1, followed by the next administration on any day in week 6 or week 12, respectively. In other embodiments, a dosing interval of about once every 6 weeks or about once every 12 weeks means that the first dose is administered on a particular day (e.g., a Monday) in week 1, followed by the next dose on the same day (e.g., a Monday) in week 6 or week 12, respectively.

[0087] As described herein, any concentration range, percentage range, ratio range, or integer range is understood to include any integer value within the recited range, and, where appropriate, fractions thereof (such as 1 / 10 and 1 / 100 of an integer), unless otherwise specified.

[0088] Various aspects of the disclosure are described in further detail in the following subsections.

[0089] II. DESCRIPTION OF EMBODIMENTS A. Methods for Treating Solid Tumors with Tucatinib and Anti-PD-1 or Anti-PD-L1 Antibodies In one aspect, the present invention provides a method for treating a solid tumor in a subject, comprising administering to the subject a combination of tucatinib, or a salt or solvate thereof, and an anti-PD-1 antibody, or an antigen-binding fragment thereof. In another aspect, the present invention provides a method for treating a solid tumor in a subject, comprising administering to the subject a combination of tucatinib, or a salt or solvate thereof, and an anti-PD-L1 antibody, or an antigen-binding fragment thereof. In some embodiments, natural killer (NK) cell infiltration is increased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, PD-1-expressing CD8+ T cell infiltration is increased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, IFNγ3-expressing CD8+ T cell infiltration is increased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, TIM3-expressing CD8+ T cell infiltration is increased in the solid tumor after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD8+ T cells expressing OX40 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells expressing FOXP3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of CD4+ T cells not expressing FOXP3 increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of Ki67-expressing CD4+ T cells increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the ratio of CD4+ T cells to CD8+ T cells increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the infiltration of neutrophils decreases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of CD11b dendritic cells increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II high-expressing macrophages increases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the percentage of MHC-II low-expressing macrophages decreases in solid tumors after administration of tucatinib, or a salt or solvate thereof. In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject to treat cancer. In some embodiments, the one or more additional therapeutic agents are an anti-CTLA4 antibody or antigen-binding fragment thereof described herein. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the CDRs of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and light chain variable region of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is ipilimumab or a biosimilar thereof. In some embodiments, the solid tumor is a HER2+ solid tumor.

[0090] In some embodiments, the solid tumor has been determined to express a mutant form of HER2. In some embodiments, the solid tumor expresses a mutant form of HER2. In some embodiments, the solid tumor contains one or more HER2 alterations. In some embodiments, the one or more HER2 alterations are HER2 mutations. In some, at least one amino acid substitution, insertion, or deletion compared to the human wild-type HER2 amino acid sequence. In some embodiments, the HER2 mutation is an activating mutation. In some embodiments, the HER2 mutation results in constitutive HER2 kinase domain activation. In some embodiments, the HER2 mutation is a mutation in the extracellular domain, the kinase domain, or the transmembrane / juxtamembrane domain, or any combination thereof. In some embodiments, the HER2 mutation is a mutation in the extracellular domain. In some embodiments, the HER2 mutation is a mutation in the extracellular domain selected from the group consisting of G309A, G309E, S310F, S310Y, C311R, C311S, and C334S. In some embodiments, the mutation in the extracellular domain is G309A. In some embodiments, the mutation in the extracellular domain is G309E. In some embodiments, the mutation in the extracellular domain is S310F. In some embodiments, the mutation in the extracellular domain is S310Y. In some embodiments, the mutation in the extracellular domain is C311R. In some embodiments, the mutation in the extracellular domain is C311S. In some embodiments, the mutation in the extracellular domain is C334S. In some embodiments, the HER2 mutation is a mutation in the kinase domain. In some embodiments, the HER2 mutation is a mutation in the kinase domain at an amino acid residue selected from the group consisting of Y772, G776, G778, and T798. In some embodiments, the mutation in the kinase domain is at Y772. In some embodiments, the mutation in the kinase domain is at G776. In some embodiments, the mutation at G776 is a G776 YVMA insertion (G776 ins YVMA). The HER2 G776 ins YVMA mutation is a mutation in which the amino acid sequence YVMA (tyrosine, valine, methionine, alanine) at positions 772 to 775 of the HER2 protein is repeated once more (also referred to as "Y772_A775dup" or "A775_G776insYVMA"). Nature. 2004 Sep 30;431(7008):525-6, and Cancer Res. 2005 Mar 1;65(5):1642-6. In some embodiments, the mutation in the kinase domain is at G778. In some embodiments, the mutation in the kinase domain is at T798. In some embodiments, the HER2 mutation is a mutation in the kinase domain selected from the group consisting of T733I, L755P, L755S, I767M, L768S, D769N, D769Y, D769H, V777L, V777M, L841V, V842I, N857S, T862A, L869R, H878Y, and R896C. In some embodiments, the mutation in the kinase domain is T733I. In some embodiments, the mutation in the kinase domain is L755P. In some embodiments, the mutation in the kinase domain is L755S. In some embodiments, the mutation in the kinase domain is I767M. In some embodiments, the mutation in the kinase domain is L768S. In some embodiments, the mutation in the kinase domain is D769N. In some embodiments, the mutation in the kinase domain is D769Y. In some embodiments, the mutation in the kinase domain is D769H. In some embodiments, the mutation in the kinase domain is V777L. In some embodiments, the mutation in the kinase domain is V777M. In some embodiments, the mutation in the kinase domain is L841V. In some embodiments, the mutation in the kinase domain is V842I. In some embodiments, the mutation in the kinase domain is N857S. In some embodiments, the mutation in the kinase domain is T862A. In some embodiments, the mutation in the kinase domain is L869R. In some embodiments, the mutation in the kinase domain is H878Y. In some embodiments, the mutation in the kinase domain is R896C. In some embodiments, the HER2 mutation is a mutation in the transmembrane / juxtamembrane domain. In some embodiments, the HER2 mutation is a mutation in the kinase domain at amino acid residue V697. In some embodiments, the HER2 mutation is a mutation in the transmembrane / juxtamembrane domain selected from the group consisting of S653C, I655V, V659E, G660D, and R678Q. In some embodiments, the mutation in the transmembrane / juxtamembrane domain is S653C. In some embodiments, the mutation in the transmembrane / juxtamembrane domain is I655V. In some embodiments, the mutation in the transmembrane / juxtamembrane domain is V659E. In some embodiments, the mutation in the transmembrane / juxtamembrane domain is G660D. In some embodiments, the mutation in the transmembrane / juxtamembrane domain is R678Q. In some embodiments, the cancer does not have HER2 amplification. In some embodiments, the cancer has been determined to be free of HER2 amplification. In some embodiments, the HER2 amplification is determined by IHC. In some embodiments, the cancer has a HER2 amplification score of 0, and the HER2 amplification score is determined by IHC. In some embodiments, the cancer has a HER2 amplification score of 1+, where the HER2 amplification score is determined by IHC. In some embodiments, the cancer has a HER2 amplification score of 0 or 1+, where the HER2 amplification score is determined by IHC. In some embodiments, if the cancer has a score of 0 as determined by IHC, HER2 is not amplified. In some embodiments, if the cancer has a score of 1+ as determined by IHC, HER2 is not amplified. In some embodiments, the cancer has less than a 2-fold increase in HER2 protein levels compared to non-cancerous tissue. In some embodiments, HER2 mutations are determined by DNA sequencing. In some embodiments, HER2 mutations are determined by RNA sequencing. In some embodiments, HER2 mutations are determined by using next-generation sequencing (NGS). In some embodiments, HER2 mutations are determined by polymerase chain reaction (PCR).

[0091] In some embodiments, the solid tumor comprises one or more HER2 alterations. In some embodiments, the one or more HER2 alterations are HER2 overexpression / amplification. In some embodiments, the cancer has a HER2 amplification score of 2+, where the HER2 amplification score is determined by immunohistochemistry (IHC). In some embodiments, the cancer has a HER2 amplification score of 3+, where the HER2 amplification score is determined by IHC. In some embodiments, if the cancer has a score of 2+ as determined by IHC, HER2 is amplified. In some embodiments, if the cancer has a score of 3+ as determined by IHC, HER2 is amplified. In some embodiments, HER2 is amplified when it is overexpressed in cancer by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175%, about 200%, about 250%, about 300%, about 350%, about 400%, about 450%, or about 500%. In some embodiments, HER2 is amplified when it is overexpressed in cancer by at least 50%. In some embodiments, HER2 is amplified when it is overexpressed in cancer by at least 75%. In some embodiments, HER2 is amplified when it is overexpressed by at least 100% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 150% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 200% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 250% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 300% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 400% in the cancer. In some embodiments, HER2 is amplified when it is overexpressed by at least 500% in the cancer. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 1.5-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 40-fold, about 50-fold, about 60-fold, about 70-fold, about 80-fold, about 90-fold, or about 100-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 1.5-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 2-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 3-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 4-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 5-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 10-fold, hi some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 15-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 20-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 25-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 30-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 40-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 50-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 60-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 70-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 80-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 90-fold. In some embodiments, HER2 is amplified when HER2 protein levels in the cancer are increased by at least about 100-fold. In some embodiments, HER2 overexpression is 3+ overexpression as determined by immunohistochemistry (IHC). In some embodiments, HER2 amplification is determined by in situ hybridization assay. In some embodiments, the in situ hybridization assay is a fluorescent in situ hybridization (FISH) assay. In some embodiments, the in situ hybridization assay is chromogenic in situ hybridization. In some embodiments, HER2 amplification is determined in tissue by NGS. In some embodiments, HER2 amplification is determined in circulating tumor DNA (ctDNA) by a blood-based NGS assay.

[0092] In some embodiments, the solid tumor is a HER2+ solid tumor. In some embodiments, the solid tumor is a metastatic solid tumor. In some embodiments, the solid tumor is locally advanced. In some embodiments, the solid tumor is unresectable. In some embodiments, the subject has been previously treated with one or more additional therapeutic agents for the solid tumor. In some embodiments, the subject has been previously treated with one or more additional therapeutic agents for the solid tumor and did not respond to the treatment. In some embodiments, the subject has been previously treated with one or more additional therapeutic agents for the solid tumor and relapsed after the treatment. In some embodiments, the subject has been previously treated with one or more additional therapeutic agents for the solid tumor and experienced disease progression during the treatment. In some embodiments, the solid tumor is sensitive to trastuzumab. In some embodiments, the solid tumor is resistant to trastuzumab. In some embodiments, the solid tumor is selected from the group consisting of cervical cancer, uterine cancer, gallbladder cancer, cholangiocarcinoma, urothelial cancer, lung cancer, breast cancer, gastroesophageal cancer, and colorectal cancer. In some embodiments, the solid tumor is cervical cancer. In some embodiments, the solid tumor is uterine cancer. In some embodiments, the solid tumor is biliary tract cancer, such as gallbladder cancer or cholangiocarcinoma. In some embodiments, the solid tumor is gallbladder cancer. In some embodiments, the solid tumor is cholangiocarcinoma. In some embodiments, the solid tumor is urothelial carcinoma. In some embodiments, the solid tumor is lung cancer. In some embodiments, the lung cancer is non-small cell lung cancer (NSCLC). In some embodiments, the NSCLC is non-squamous NSCLC. In some embodiments, the solid tumor is breast cancer. In some embodiments, the breast cancer is HER2+ breast cancer. In some embodiments, the breast cancer is hormone receptor positive (HR+) breast cancer. In some embodiments, the breast cancer is hormone receptor negative (HR-) breast cancer. In some embodiments, the breast cancer is triple negative breast cancer. In some embodiments, the solid tumor is gastroesophageal cancer. In some embodiments, the solid tumor is colorectal cancer. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express PD-1. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the cancer cells from the subject express PD-L1. In some embodiments, at least about 0.1%, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of T cells from a subject express CTLA4.

[0093] In some embodiments, the HER2 status of the sample cells is determined. This determination can be made before the start of treatment (i.e., administration of tucatinib), during treatment, or after treatment has ended. In some cases, determining the HER2 status leads to a decision to change treatment (e.g., add an anti-HER2 antibody to the treatment regimen, discontinue use of tucatinib, discontinue treatment altogether, or switch from another treatment to the method of the present invention).

[0094] In some embodiments, the sample cells are cancer cells. In some cases, the sample cells are obtained from a subject with cancer. The sample cells can be obtained as a biopsy specimen by surgical resection or as a fine needle aspiration (FNA). In some embodiments, the sample cells are circulating tumor cells (CTCs).

[0095] HER2 expression can be compared with reference cells. In some embodiments, the reference cells are non-cancerous cells obtained from the same subject as the sample cells. In other embodiments, the reference cells are non-cancerous cells obtained from a different subject or a population of subjects. In some embodiments, measuring HER2 expression includes, for example, determining HER2 gene copy number or amplification, nucleic acid sequencing (e.g., sequencing of genomic DNA or cDNA or RNA sequencing), measuring mRNA expression, measuring protein abundance, or a combination thereof. HER2 testing methods include immunohistochemistry (IHC), in situ hybridization, fluorescent in situ hybridization (FISH), chromogenic in situ hybridization (CISH), ELISA, and RNA quantification (e.g., quantification of HER2 expression) using techniques such as RT-PCR and microarray analysis.

[0096] In some embodiments, the presence or absence of HER2 mutation is confirmed by, for example, collecting tumor tissue from cancer patients and performing methods such as real-time quantitative PCR (qRT-PCR) or microarray analysis. In some embodiments, the tumor tissue is formalin-fixed paraffin-embedded (FFPE) specimen. In some embodiments, the presence or absence of HER2 mutation is confirmed by collecting circulating tumor DNA (ctDNA) from cancer patients and performing methods such as next-generation sequencing (NGS) (J Clin Oncol 2013;31:1997-2003, Clin Cancer Res 2012;18:4910-8, J Thorac Oncol 2012;7:85-9, Lung Cancer 2011;74:139-44, Cancer Res 2005;65:1642-6, Cancer Sci 2006;97:753-9, and ESMO Open 2017;2:e000279).

[0097] The nucleic acid used to detect HER2 mutation in any of the methods described herein includes genomic DNA, RNA transcribed from genomic DNA, and cDNA generated from RNA.Nucleic acid can be derived from vertebrate, for example, mammal.When nucleic acid is a copy of the nucleic acid found in a specific source, it can be said to be directly derived from that specific source or "derived" from that specific source.

[0098] In certain embodiments, the nucleic acid comprises a copy of the nucleic acid, e.g., a copy resulting from amplification. For example, in some cases, amplification may be desirable to obtain a desired amount of material for detecting mutations. The amplicon can then be subjected to a mutation detection method, such as those described below, to determine whether a mutation is present in the amplicon.

[0099] Somatic mutations or variations can be detected by specific methods known to those skilled in the art. Such methods include, but are not limited to, DNA sequencing, primer-containing somatic mutation-specific nucleotide incorporation assays and somatic mutation-specific primer extension assays (e.g., somatic mutation-specific PCR, somatic mutation-specific ligation chain reaction (LCR), and gap-LCR extension assays), mutation-specific oligonucleotide hybridization assays (e.g., oligonucleotide ligation assays), cleavage protection assays that detect fluorinated bases in nucleic acid duplexes using protection from cleaving agents, electrophoretic analysis that compares the mobility of mutant and wild-type nucleic acid molecules, denaturing gradient gel electrophoresis (e.g., DGGE, such as Myers et al. (1985) Nature 313:495), analysis of RNase cleavage at uninched base pairs, analysis by chemical or enzymatic cleavage of heteroduplex DNA, mass spectrometry (e.g., MALDI-TOF); genetic bit analysis (GBA), 5' nuclease assays (e.g., TaqMan™), and assays using molecular pathway labels.

[0100] Detection of variations in target nucleic acids can be achieved by molecular cloning and sequencing of the target nucleic acid using techniques well known in the art. Alternatively, amplification techniques such as polymerase chain reaction (PCR) can be used to directly amplify the target nucleic acid sequence from genomic DNA preparations derived from tumor tissue. The nucleic acid sequence of the amplified sequence can then be determined, and variations can be identified therefrom. Amplification techniques are well known in the art, for example, polymerase chain reaction is described in Saiki et al., Science 239:487, 1988; U.S. Patent Nos. 4,683,203 and 4,683,195.

[0101] Ligase chain reaction, known in the art, can also be used to amplify target nucleic acid sequences. See, for example, Wu et al., Genomics 4:560-569 (1989). A technique known as allele-specific PCR can also be used to detect somatic mutations (e.g., substitutions). See, for example, Ruano and Kidd (1989) Nucleic Acids Research 17:8392; McClay et al. (2002) Analytical Biochem. 301:200-206. In certain embodiments of this technique, the 3'-terminal nucleotide of the primer is complementary to (i.e., specifically base pairs with) a specific mutation in the target nucleic acid. A mutation-specific primer is used. If the specific mutation is not present, no amplification product is observed. An amplification-resistant mutation system (ARMS) can also be used to detect mutations (e.g., substitutions). ARMS are described, for example, in European Patent Application Publication No. 0332435, and Newton et al., Nucleic Acids Research, 17:7, 1989.

[0102] Other methods useful for detecting variations (e.g., substitutions) include: (1) mutation-specific nucleotide incorporation assays, e.g., single-base extension assays (see, e.g., Chen et al. (2000) Genome Res. 10:549-557); (2) mutation-specific primer extension assays (see, e.g., Ye et al. (2001) Hum. Mut. 17:305-316); (3) 5' nuclease assays (see, e.g., De La Vega et al. (2002) BioTechniques 32:S48-S54 (describing TaqMan® assays); (4) assays using molecular pathway labels (see, e.g., Tyagi et al. (1998) Nature Biotech. 16:49-53); (5) oligonucleotide ligation assays (see, e.g., Grossman et al. (1994) Nuc. Acids Res. 22:4527-4534) and (6) allele-specific PCR.

[0103] Diversity can also be detected by mismatch detection methods. A mismatch is a hybridized nucleic acid duplex that is not 100% complementary. The lack of full complementarity can be due to deletions, insertions, inversions, or substitutions. One example of a mismatch detection method is the mismatch repair detection (MRD) assay described, for example, in Faham et al., Proc. Natl. Acad. Sci. USA 102:14717-14722 (2005). Another example of mismatch cleavage technology is the RNase protection method detailed in Myers et al., Science 230:1242, 1985. For example, a method used to detect diversity can include the use of a labeled riboprobe complementary to a human wild-type target nucleic acid. The riboprobe and the target nucleic acid from a tissue sample can be annealed (hybridized) together, followed by digestion with RNase A enzyme to detect some mismatches in the double-stranded RNA structure. When a mismatch is detected by RNase A, it is cleaved at the site of the mismatch. Thus, if a mismatch is detected and cleaved by RNase A, an RNA product smaller than the mRNA or full-length double-stranded RNA of the DNA and riboprobe will be observed when the annealed RNA preparation is separated on an electrophoresis gel matrix. The riboprobe does not need to be the full-length target nucleic acid, but can be a portion of the target nucleic acid as long as it includes the position suspected of having a mutation.

[0104] In a similar manner, DNA probes can be used to detect mismatches, for example, through enzymatic or chemical cleavage. For example, Cotton et al., Proc. Natl. Acad. Sci. USA, 85:4397, 1988. Alternatively, mismatches can be detected by the change in electrophoretic mobility of mismatched duplexes relative to matched duplexes. For example, see Cariello, Human Genetics, 42:726, 1988. Using either riboprobes or DNA probes, target nucleic acids suspected of containing mutations can be amplified before hybridization. Changes in target nucleic acids can also be detected using Southern hybridization, especially when rearrangements such as deletions and insertions are drastic changes.

[0105] Restriction fragment length polymorphism (RFLP) probes for the target nucleic acid or surrounding marker genes can also be used to detect variations, such as insertions or deletions. Insertions and deletions can also be detected by cloning, sequencing, and amplifying the target nucleic acid. Single-stranded PCR polymorphism (SSCP) assays can also be used to detect base-change variants of alleles. SSCP can be modified for the detection of ErbB2 somatic mutations. SSCP reveals base differences resulting from changes in the electrophoretic shift of single-stranded PCR products. Single-stranded PCR products can be generated by heating or otherwise denaturing double-stranded PCR products. Single-stranded nucleic acids can refold or form secondary structures that are partially dependent on the base sequence. Differences in electrophoretic mobility of single-stranded amplification products are related to differences in the base sequence at the SNP position. Denaturing gradient gel electrophoresis (DGGE) distinguishes SNP alleles based on the sequence-dependent differences in stability and melting properties inherent in polymorphic DNA and the corresponding differences in electrophoretic migration patterns in denaturing gradient gels.

[0106] Somatic mutations or modifications can also be detected using microarrays. Microarrays are typically multiplex technologies that use an array of thousands of nucleic acid probes to hybridize with, for example, cDNA or cRNA samples under high stringency conditions. To determine the relative abundance of nucleic acid sequences in the target, the hybridization of the probes with the target is typically detected and quantified by detecting fluorescent dye-, silver-, or chemiluminescent-labeled targets. In a typical microarray, the probes are bound to a hard surface by covalent bonding to a chemical matrix (e.g., via epoxy-silane, amino-silane, lysine, polyacrylamide, etc.). The hard surface can be, for example, glass, a silicon chip, or microbeads.

[0107] Another method for detecting somatic mutations is based on mass spectrometry. Mass spectrometry uses the unique mass of each of the four nucleotides in DNA. ErbB2 nucleic acids containing potential mutations can be clearly analyzed by mass spectrometry by measuring the mass difference from nucleic acids containing somatic mutations. MALDI-TOF (matrix-assisted laser desorption / ionization time-of-flight) mass spectrometry technology is useful for highly accurate measurement of the molecular weight of nucleic acids containing somatic mutations. Many approaches to nucleic acid analysis have been developed based on mass spectrometry. Exemplary mass spectrometry-based methods include primer extension assays, which can be used in combination with other approaches such as traditional gel-based formats and microarrays.

[0108] Sequence-specific ribozymes (U.S. Patent No. 5,498,531) can also be used to detect somatic mutations based on the development or loss of ribozyme cleavage sites. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or differences in melting temperatures. If the mutation affects a restriction enzyme cleavage site, the mutation can be identified by changes in restriction enzyme digestion patterns and corresponding changes in nucleic acid fragment lengths as determined by gel electrophoresis.

[0109] In certain embodiments of the present disclosure, protein-based detection techniques are used to detect variant proteins encoded by genes containing the genetic variations disclosed herein. Determining the presence of variant forms of proteins can be performed by any suitable technique known in the art, such as electrophoresis (e.g., denaturing or non-denaturing polyacrylamide gel electrophoresis, two-dimensional gel electrophoresis, capillary electrophoresis). Electrophoresis and isoelectric focusing, chromatography (e.g., size chromatography, high-performance liquid chromatography (HPLC), and ion-exchange HPLC), mass spectrometry (e.g., MALDI-TOF mass spectrometry, electrospray), electron ionization (ESI) mass spectrometry, and tandem mass spectrometry). See, for example, Ahler and Jungabauer (2006) J. Chromatog. B. Analyt. Technol. Biomed. Life Sci. 841:110-122. Suitable techniques can be selected based in part on the nature of the variation to be detected. For example, variations in amino acid substitutions resulting in amino acid substitutions with a different charge from the original amino acid can be detected by isoelectric focusing. Isoelectric focusing involves passing a polypeptide through a pH gradient gel at high voltage, separating proteins by their isoelectric point (pi). The pH gradient gel can be compared to a gel containing the wild-type protein being run at the same time. If the mutation results in the creation of a new proteolytic cleavage site or the abolition of an existing cleavage site, the sample can be peptide mapped by protein digestion followed by appropriate electrophoresis, chromatography, or mass spectrometry techniques. The presence of variations can also be detected using protein sequencing techniques such as Edman degradation or certain forms of mass spectrometry.

[0110] The method known in the art that uses the combination of these techniques can also be used.For example, in HPLC-microscope tandem mass spectrometry technique, protein is subjected to proteolytic digestion, and the resulting peptide mixture is separated by reversed-phase chromatography.Then, tandem mass spectrometry is carried out, and the data collected therefrom is analyzed.In another example, non-denaturing gel electrophoresis is combined with MALDI mass spectrometry.

[0111] In certain embodiments, proteins can be isolated from a sample using reagents such as antibodies or peptides that specifically bind to the protein, and then further analyzed using any of the techniques disclosed above to reveal genetic diversity.

[0112] Alternatively, the presence of a variant protein in a sample can be detected by an antibody specific to the protein with genetic variation, i.e., an antibody that specifically binds to the protein with the mutation but not to the protein without the mutation. This can be detected by an immunoaffinity assay. Such antibodies can be generated by any suitable technique known in the art. The antibody can be used to immunoprecipitate a specific protein from a solution sample or, for example, to immunoblot proteins separated by polyacrylamide gel. Immunocytochemical methods can also be used to detect specific protein variants in tissues or cells. For example, enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), immunoradiometric assays (IRMAs), and immunoenzymatic assays (IEMAs), including sandwich assays, use monoclonal or polyclonal antibodies.

[0113] B. Tucatinib Dosage and Administration In some embodiments, the dose of tucatinib is between about 0.1 mg / kg and 10 mg / kg of the subject's body weight (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 mg / kg of the subject's body weight). In other embodiments, the dose of tucatinib is between about 10 mg / kg and 100 mg / kg of the subject's body weight (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg / kg of the subject's body weight). In some embodiments, the dose of tucatinib is at least about 100 mg / kg to 500 mg / kg of the subject's body weight (e.g., at least about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 mg / kg of the subject's body weight). In certain embodiments, the dose of tucatinib is between about 1 mg / kg and 50 mg / kg of the subject's body weight (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 mg / kg of the subject's body weight). In some cases, the dose of tucatinib is about 50 mg / kg of the subject's body weight.

[0114] In some embodiments, a dose of tucatinib comprises between about 1 mg and 100 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg) of tucatinib. In other embodiments, a dose of tucatinib is between about 100 mg and 1,000 mg (e.g., about 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, In some embodiments, the dose of tucatinib is about 150 mg to about 650 mg. In some embodiments, the dose of tucatinib is about 300 mg. In certain embodiments, the dose of tucatinib is about 300 mg (e.g., when administered twice daily).

[0115] In some embodiments, a dose of tucatinib is at least about 1,000 mg to 10,000 mg (e.g., at least about 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 3,900, 3,100, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 4,100, 4,200, 4,300, 4,400, 4,500, 5,600, 5,700, 5,800, 5,900, 6,100, 6,100, 6,200, 6,300, 6,400, 6,500, 7,100, 7,200, 7,300, 7,400, 7,500, 8,500, 8,600, 8,700, 8,800, 9,900, 10,1 ... ,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5 ,200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500, 6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500, 7,600, 7,700, 7 9,000, 9,100, 9,200, 9,300, 9,400, 9,500, 9,600, 9,700, 9,800, 9,900, 10,000 mg or more of tucatinib.

[0116] In some embodiments, a dose of tucatinib, or a salt or solvate thereof, contains a therapeutically effective amount of tucatinib, or a salt or solvate thereof. In other embodiments, a dose of tucatinib, or a salt or solvate thereof, contains less than a therapeutically effective amount of tucatinib, or a salt or solvate thereof (e.g., when multiple doses are administered to achieve a desired clinical or therapeutic effect).

[0117] Tucatinib, or a salt or solvate thereof, can be administered by any suitable route and manner. Suitable routes for administering small molecules of the present invention are well known in the art and can be selected by those of skill in the art. In one embodiment, tucatinib, or a salt or solvate thereof, is administered parenterally. Parenteral administration refers to a mode of administration other than enteral or topical administration, usually by injection, and includes intraepidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion. In some embodiments, the route of administration of tucatinib, or a salt or solvate thereof, is intravenous injection or infusion. In some embodiments, the route of administration of tucatinib, or a salt or solvate thereof, is intravenous infusion. In some embodiments, the route of administration of tucatinib, or a salt or solvate thereof, is intravenous injection or infusion. In some embodiments, tucatinib, or a salt or solvate thereof, is administered by intravenous infusion. In some embodiments, the route of administration of tucatinib, or a salt or solvate thereof, is oral.

[0118] In one embodiment of the methods or uses or products for use provided herein, tucatinib, or a salt or solvate thereof, is administered to a subject once daily, twice daily, three times daily, or four times daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject every other day, about once every week, or about once every three weeks. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject once daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject at a dose of about 300 mg twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject at a dose of 300 mg twice daily. In some embodiments, tucatinib, or a salt or solvate thereof, is administered to a subject at a dose of about 600 mg once daily. In some embodiments, tucatinib or its salt or solvate is administered to a subject at a dose of 600 mg once a day.In some embodiments, tucatinib or its salt or solvate is administered to a subject twice a day on each day of a 21-day treatment cycle.In some embodiments, tucatinib or its salt or solvate is administered to a subject orally.

[0119] C. Anti-PD-1 antibody Generally, the anti-PD-1 antibodies or antigen-binding fragments thereof of the present disclosure bind to PD-1, e.g., human PD-1. In some embodiments, the anti-PD-1 antibodies or antigen-binding fragments thereof comprise the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises the CDRs of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003, or a biosimilar thereof. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab. See U.S. Patent Nos. 8,354,509 and 8,900,587. The pembrolizumab antibody is also known as KEYTRUDA®. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is nivolumab. See, e.g., U.S. Patent Nos. 8,008,449; WO 2013 / 173223; and WO 2006 / 121168. The nivolumab antibody is also known as OPDIVO®. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is Amp-514. See, e.g., Naing et al., Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, p. 1072P. The Amp-514 antibody is also known as MEDI0680. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is tislelizumab. See, e.g., U.S. Patent No. 9,834,606. The tislelizumab antibody is also known as BGB-A317. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is cemiplimab. See, e.g., Burova et al., Mol Cancer Ther. 2017 May;16(5):861-870. The cemiplimab antibody is also known as REGN2810. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is TSR-042 (readily available on the World Wide Web at www.ejcancer.com / article / S0959-8049(16)32902-1 / pdf). In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is JNJ-63723283. See, e.g., Calvo et al., Journal of Clinical Oncology 36, no. 5_suppl (February 2018) 58-58. The JNJ-63723283 antibody is also known as JNJ-3283. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is CBT-501. See, e.g., Patel et al., Journal for ImmunoTherapy of Cancer, 2017, 5(Suppl 2):P242. The CBT-501 antibody is also known as genolimuzumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is PF-06801591. See, e.g., Youssef et al., Proceedings of the American Association for Cancer Research Annual Meeting 2017; Cancer Res 2017; 77(13 Suppl):Abstract. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is JS-001. See, e.g., US2016 / 0272708. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is camrelizumab. See, e.g., US Patent Publication No. US2016 / 376367; Huang et al., Clinical Cancer Research 2018 Mar 15;24(6):1296-1304. The camrelizumab antibody is also known as SHR-1210 and INCSHR-1210. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is PDR001. See, e.g., WO2017 / 106656; Naing et al., Journal of Clinical Oncology 34, no. 15_suppl (May 2016) 3060-3060. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is BCD-100. See, e.g., WO2018 / 103017. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is AGEN2034. See, e.g., WO2017 / 040790. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is IBI-308. See, e.g., WO2017 / 024465; WO2017 / 133540. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is BI-754091. See, e.g., U.S. Patent Publication No. US2017 / 334995; Johnson et al., Journal of Clinical Oncology 36, no. 5_suppl (February 2018) 212-212. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is GLS-010. See, e.g., WO2017 / 025051. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is LZM-009. See, e.g., U.S. Patent Publication No. US2017 / 210806. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is AK-103. See, e.g., WO2017 / 071625; WO2017 / 166804; WO2018 / 036472. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is MGA-012. See, e.g., WO2017 / 019846. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is Sym-021. See, e.g., WO2017 / 055547. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is CS1003. See, e.g., CN107840887.

[0120] The anti-PD-1 antibodies of the present disclosure are preferably monoclonal, and can be multispecific, human, humanized, or chimeric antibodies, single-chain antibodies, Fab fragments, F(ab') fragments, fragments produced by an Fab expression library, and PD-1-binding fragments of any of the above. In some embodiments, the anti-PD-1 antibodies described herein specifically bind to PD-1 (e.g., human PD-1). The immunoglobulin molecules of the present disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.

[0121] In certain embodiments of the present disclosure, the antibody is an antigen-binding fragment (e.g., a human antigen-binding fragment) as described herein, including, but not limited to, Fab, Fab' and F(ab'), Fd, single-chain Fv (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), and V L or V H Antigen-binding fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with all or part of the following: hinge region, CH1, CH2, CH3, and CL domains. Also included in the disclosure are antigen-binding fragments comprising any combination of the variable region(s) and the hinge region, CH1, CH2, CH3, and CL domains. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken.

[0122] The anti-PD-1 antibodies of the present disclosure may be monospecific, bispecific, trispecific, or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of PD-1, or may be specific for both PD-1 and heterologous proteins. See, e.g., PCT Publications WO93 / 17715; WO92 / 08802; WO91 / 00360; WO92 / 05793; Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., 1992, J. Immunol. 148:1547-1553.

[0123] The anti-PD-1 antibodies of the disclosure can be described or specified in terms of the particular CDRs they contain.The exact amino acid sequence boundaries of a given CDR or FR can be determined using the Kabat numbering scheme (Kabat et al., 1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD; Al-Lazikani et al., (1997) JMB 273, 927-948 (Chothia numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745 (Contact numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol., 2003 Jan;27(1):55-77 (the "IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol,2001 Jun 8;309(3):657-70, (the "Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS,1989,86(23):9268-9272 (the "AbM" numbering scheme). The boundaries of a given CDR may vary depending on the scheme used to identify it. In some embodiments, the "CDR" or "complementarity determining region" of a given antibody or region thereof (e.g., its variable region), or each specific CDR (e.g., CDR-H1, CDR-H2, CDR-H3), will be understood to encompass one (or a specific) CDR defined by any of the above schemes. For example, if a specific CDR (e.g., CDR-H3) is located within a given V H or V L When a region amino acid sequence is described as containing the amino acid sequence of a corresponding CDR, it is understood that such CDR has the sequence of the corresponding CDR (e.g., CDR-H3) in the variable region defined by any of the above schemes. Schemes for identifying a particular CDR or multiple particular CDRs can be designated as CDRs defined by the Kabat, Chothia, AbM, or IMGT methods.

[0124] In some embodiments, the numbering of amino acid residues in the CDR sequences of the anti-PD-1 antibodies or antigen-binding fragments thereof provided herein is according to the IMGT numbering scheme described in Lefranc, MP et al., Dev. Comp. Immunol., 2003, 27, 55-77.

[0125] In some embodiments, the numbering of amino acid residues in the CDR sequences of the anti-PD-1 antibodies or antigen-binding fragments thereof provided herein is according to the Kabat numbering scheme described in Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242.

[0126] In some embodiments, the anti-PD-1 antibody of the present disclosure comprises the CDRs of the nivolumab antibody. See WO2006 / 121168. In some embodiments, the CDRs of the nivolumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses an anti-PD-1 antibody or derivative thereof comprising a heavy or light chain variable domain, the variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody nivolumab, and (b) a set of four framework regions, the set of framework regions being different from the set of framework regions of the monoclonal antibody nivolumab, and the anti-PD-1 antibody or derivative thereof binds to PD-1. In certain embodiments, the anti-PD-1 antibody is nivolumab. The nivolumab antibody is also known as OPDIVO®.

[0127] In some embodiments, the anti-PD-1 antibodies of the present disclosure comprise the CDRs of the pembrolizumab antibody. See U.S. Patent Nos. 8,354,509 and 8,900,587. In some embodiments, the CDRs of the pembrolizumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses anti-PD-1 antibodies or derivatives thereof comprising a heavy or light chain variable domain, the variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody pembrolizumab, and (b) a set of four framework regions that differ from the set of framework regions of the monoclonal antibody pembrolizumab, wherein the anti-PD-1 antibody or derivative thereof binds to PD-1. In certain embodiments, the anti-PD-1 antibody is pembrolizumab. The pembrolizumab antibody is also known as KEYTRUDA® (Merck & Co., Inc., Kenilworth, NJ, USA).

[0128] In some embodiments, the anti-PD-1 antibody is a monoclonal antibody.

[0129] In some embodiments, the anti-PD-1 antibody is nivolumab, also known as the OPDIVO® antibody, described in WO2006 / 121168.

[0130] In some embodiments, the anti-PD-1 antibody is pembrolizumab, also known as the KEYTRUDA® antibody, which is described in U.S. Patent Nos. 8,354,509 and 8,900,587.

[0131] The anti-PD-1 antibodies of the invention may also be described or specified in terms of their binding affinity to PD-1 (e.g., human PD-1). Preferred binding affinities include those with a binding affinity of 5×10 -2 M, 10 -2 M, 5 x 10 -3 M, 10 -3 M, 5 x 10 -4 M, 10 -4 M, 5 x 10 -5 M, 10 -5 M, 5 x 10 -6 M, 10 -6 M, 5 x 10 -7 M, 10 -7 M, 5 x 10 -8 M, 10 -8 M, 5 x 10 -9 M, 10 -9 M, 5 x 10 -10 M, 10 -10 M, 5 x 10 -11 M, 10 -11 M, 5 x 10 -12 M, 10 -12 M, 5 x 10 -13 M, 10 -13 M, 5 x 10 -14 M, 10 -14 M, 5 x 10 -15 M, or 10 -15 Those with a dissociation constant or Kd less than M are included.

[0132] There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with a heavy chain designated α, δ, ε, γ, and μ. The γ and α classes are further divided into subclasses; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. IgG1 antibodies can exist in multiple polymorphic variants called allotypes (reviewed in Jefferis and Lefranc 2009. mAbs Vol 1 Issue 4 1-7), any of which are suitable for use in some of the embodiments herein. Common allotypic variants in the human population are designated by the letters a, f, n, z, or combinations thereof. In any of the embodiments herein, the antibody can comprise a heavy chain Fc region comprising a human IgG Fc region. In a further embodiment, the human IgG Fc region comprises human IgG1.

[0133] Antibodies also include modified derivatives, i.e., derivatives modified such that any type of molecule is covalently attached to the antibody such that the covalent attachment does not inhibit the antibody's binding to PD-1. For example, but not limited to, antibody derivatives include antibodies modified by, e.g., glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, derivatives may contain one or more unconventional amino acids.

[0134] The anti-PD-1 antibodies or antigen-binding fragments thereof described herein can be administered by any suitable route and manner. Suitable routes for administering the antibodies or antigen-binding fragments thereof of the present invention are well known in the art and can be selected by one of ordinary skill in the art. In one embodiment, the anti-PD-1 antibodies or antigen-binding fragments thereof described herein are administered parenterally. Parenteral administration refers to a mode of administration other than enteral or topical administration, usually by injection, and includes intraepidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion. In some embodiments, the route of administration of the anti-PD-1 antibodies or antigen-binding fragments thereof described herein is intravenous infusion. In some embodiments, the route of administration of the anti-PD-1 antibodies or antigen-binding fragments thereof described herein is intravenous injection or infusion. In some embodiments, the route of administration of the anti-PD-1 antibodies or antigen-binding fragments thereof described herein is oral.

[0135] D. Anti-PD-L1 antibody Generally, the anti-PD-L1 antibodies or antigen-binding fragments thereof of the present disclosure bind to PD-L1, e.g., human PD-L1. In some embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof comprise the complementarity-determining regions (CDRs) of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or biosimilars thereof. In some embodiments, the anti-PD-L1 antibodies or antigen-binding fragments thereof comprise the CDRs of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof comprises the heavy chain variable region and the light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, embafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, embafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is atezolizumab. See U.S. Patent No. 8,217,149. The atezolizumab antibody is also known as TECENTRIQ®. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is BMS-936559. See U.S. Patent No. 7,943,743 (also referred to as 12A4). In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab. The durvalumab antibody is also known as IMFINZI®. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is avelumab. The avelumab antibody is also known as BAVENCIO®. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is envafolimab. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is CK-301. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is CS-1001. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is SHR-1316. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is CBT-502. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is BGB-A333. See Akinleye and Rasool, J. Hematol. Oncol., 2019, 12:92.

[0136] The anti-PD-L1 antibodies of the present disclosure are preferably monoclonal, and may be multispecific, human, humanized, or chimeric antibodies, single-chain antibodies, Fab fragments, F(ab') fragments, fragments produced by an Fab expression library, and PD-L1-binding fragments of any of the above. In some embodiments, the anti-PD-L1 antibodies described herein specifically bind to PD-L1 (e.g., human PD-L1). The immunoglobulin molecules of the present disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule.

[0137] In certain embodiments of the present disclosure, the antibody is an antigen-binding fragment (e.g., a human antigen-binding fragment) as described herein, including, but not limited to, Fab, Fab' and F(ab'), Fd, single-chain Fv (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), and V L or V H Antigen-binding fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with all or part of the following: hinge region, CH1, CH2, CH3, and CL domains. Also included in the disclosure are antigen-binding fragments comprising any combination of the variable region(s) and the hinge region, CH1, CH2, CH3, and CL domains. In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof is human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken.

[0138] The anti-PD-L1 antibodies of the present disclosure may be monospecific, bispecific, trispecific, or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of PD-L1, or may be specific for both PD-L1 and heterologous proteins. See, e.g., PCT Publications WO93 / 17715; WO92 / 08802; WO91 / 00360; WO92 / 05793; Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., 1992, J. Immunol. 148:1547-1553.

[0139] The anti-PD-L1 antibodies of the disclosure may be described or specified in terms of the particular CDRs they contain.The exact amino acid sequence boundaries of a given CDR or FR can be determined using the Kabat numbering scheme (Kabat et al., 1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD; Al-Lazikani et al., (1997) JMB 273, 927-948 (Chothia numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745 (Contact numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol., 2003 Jan;27(1):55-77 (the "IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol,2001 Jun 8;309(3):657-70, (the "Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS,1989,86(23):9268-9272 (the "AbM" numbering scheme). The boundaries of a given CDR may vary depending on the scheme used to identify it. In some embodiments, the "CDR" or "complementarity determining region" of a given antibody or region thereof (e.g., its variable region), or each specific CDR (e.g., CDR-H1, CDR-H2, CDR-H3), will be understood to encompass one (or a specific) CDR defined by any of the above schemes. For example, if a specific CDR (e.g., CDR-H3) is located within a given V H or V L When a region amino acid sequence is described as containing the amino acid sequence of a corresponding CDR, it is understood that such CDR has the sequence of the corresponding CDR (e.g., CDR-H3) in the variable region defined by any of the above schemes. Schemes for identifying a particular CDR or multiple particular CDRs can be designated as CDRs defined by the Kabat, Chothia, AbM, or IMGT methods.

[0140] In some embodiments, the numbering of the amino acid residues in the CDR sequences of the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein is according to the IMGT numbering scheme described in Lefranc, MP et al., Dev. Comp. Immunol., 2003, 27, 55-77.

[0141] In some embodiments, the numbering of the amino acid residues in the CDR sequences of the anti-PD-L1 antibodies or antigen-binding fragments thereof provided herein is according to the Kabat numbering scheme as described in Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242.

[0142] In some embodiments, the anti-PD-L1 antibodies of the present disclosure comprise the CDRs of the atezolizumab antibody. See U.S. Patent No. 8,217,149. In some embodiments, the CDRs of the atezolizumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses anti-PD-L1 antibodies or derivatives thereof comprising a heavy or light chain variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody atezolizumab, and (b) a set of four framework regions, which framework regions differ from the set of framework regions of the monoclonal antibody atezolizumab, and which bind to PD-L1. In certain embodiments, the anti-PD-L1 antibody is atezolizumab, which is also known as TECENTRIQ®.

[0143] In some embodiments, the anti-PD-L1 antibodies of the present disclosure comprise the CDRs of the BMS-936559 antibody. See U.S. Patent No. 7,943,743 (also referred to as 12A4). In some embodiments, the CDRs of the BMS-936559 antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses anti-PD-L1 antibodies or derivatives thereof comprising a heavy or light chain variable domain comprising (a) a set of three CDRs, which set of CDRs is derived from monoclonal antibody BMS-936559, and (b) a set of four framework regions, which set of framework regions differs from the set of framework regions of monoclonal antibody BMS-936559, wherein the anti-PD-L1 antibody or derivative thereof binds to PD-L1. In a specific embodiment, the anti-PD-L1 antibody is BMS-936559.

[0144] In some embodiments, the anti-PD-L1 antibody of the present disclosure comprises the CDRs of the durvalumab antibody. In some embodiments, the CDRs of the durvalumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses anti-PD-L1 antibodies or derivatives thereof comprising a heavy or light chain variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody durvalumab, and (b) a set of four framework regions that differ from the set of framework regions of the monoclonal antibody durvalumab, and wherein the anti-PD-L1 antibody or derivative thereof binds to PD-L1. In certain embodiments, the anti-PD-L1 antibody is durvalumab. The durvalumab antibody is also known as IMFINZI®.

[0145] In some embodiments, the anti-PD-L1 antibody of the present disclosure comprises the CDRs of the avelumab antibody. In some embodiments, the CDRs of the avelumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses anti-PD-L1 antibodies or derivatives thereof comprising a heavy or light chain variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody avelumab, and (b) a set of four framework regions that differ from the set of framework regions of the monoclonal antibody avelumab, and wherein the anti-PD-L1 antibody or derivative thereof binds to PD-L1. In certain embodiments, the anti-PD-L1 antibody is avelumab. The avelumab antibody is also known as BAVENCIO®.

[0146] In some embodiments, the anti-PD-L1 antibody is a monoclonal antibody.

[0147] The anti-PD-L1 antibodies of the invention may also be described or specified in terms of their binding affinity to PD-L1 (e.g., human PD-L1). Preferred binding affinities include those with a binding affinity of 5×10 -2 M, 10 -2 M, 5 x 10 -3 M, 10 -3 M, 5 x 10 -4 M, 10 -4 M, 5 x 10 -5 M, 10 -5 M, 5 x 10 -6 M, 10 -6 M, 5 x 10 -7 M, 10 -7 M, 5 x 10 -8 M, 10 -8 M, 5 x 10-9 M, 10 -9 M, 5 x 10 -10 M, 10 -10 M, 5 x 10 -11 M, 10 -11 M, 5 x 10 -12 M, 10 -12 M, 5 x 10 -13 M, 10 -13 M, 5 x 10 -14 M, 10 -14 M, 5 x 10 -15 M, or 10 -15 Those with a dissociation constant or Kd less than M are included.

[0148] There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with a heavy chain designated α, δ, ε, γ, and μ. The γ and α classes are further divided into subclasses; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. IgG1 antibodies can exist in multiple polymorphic variants called allotypes (reviewed in Jefferis and Lefranc 2009. mAbs Vol 1 Issue 4 1-7), any of which are suitable for use in some of the embodiments herein. Common allotypic variants in the human population are designated by the letters a, f, n, z, or combinations thereof. In any of the embodiments herein, the antibody can comprise a heavy chain Fc region comprising a human IgG Fc region. In a further embodiment, the human IgG Fc region comprises human IgG1.

[0149] Antibodies also include modified derivatives, i.e., derivatives modified such that any type of molecule is covalently attached to the antibody such that the covalent attachment does not interfere with the binding of the antibody to PD-L1. For example, without limitation, antibody derivatives include antibodies that have been modified by, e.g., glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Furthermore, derivatives may contain one or more unconventional amino acids.

[0150] The anti-PD-L1 antibodies or antigen-binding fragments thereof described herein can be administered by any suitable route and manner. Suitable routes for administering the antibodies or antigen-binding fragments thereof of the invention are well known in the art and can be selected by one of skill in the art. In one embodiment, the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein are administered parenterally. Parenteral administration refers to modes of administration other than enteral and topical administration, usually by injection, and includes intraepidermal, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intrathecal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion. In some embodiments, the route of administration of the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein is intravenous infusion. In some embodiments, the route of administration of the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein is intravenous injection or infusion. In some embodiments, the route of administration of the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein is oral.

[0151] E. Anti-CTLA4 antibody Generally, the anti-CTLA4 antibodies or antigen-binding fragments thereof of the present disclosure bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA4), e.g., human CTLA4. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof comprise the complementarity-determining regions (CDRs) of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof comprise the CDRs of ipilimumab. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof comprise the heavy chain variable region and light chain variable region of ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof comprise the heavy chain variable region and light chain variable region of ipilimumab. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof are ipilimumab or a biosimilar thereof. In some embodiments, the anti-CTLA4 antibodies or antigen-binding fragments thereof are ipilimumab. The ipilimumab antibody is also known as YERVOY®.

[0152] Anti-CTLA4 antibodies of the present disclosure are preferably monoclonal and may be multispecific, human, humanized, or chimeric antibodies, single-chain antibodies, Fab fragments, F(ab') fragments, fragments produced by an Fab expression library, and CTLA4-binding fragments of any of the above. In some embodiments, the anti-CTLA4 antibodies described herein specifically bind to CTLA4 (e.g., human CTLA4). The immunoglobulin molecules of the present disclosure may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.

[0153] In certain embodiments of the present disclosure, the antibody is an antigen-binding fragment (e.g., a human antigen-binding fragment) as described herein, including, but not limited to, Fab, Fab' and F(ab'), Fd, single-chain Fv (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), and V L or V HAntigen-binding fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with all or part of the following: hinge region, CH1, CH2, CH3, and CL domains. Also included in the disclosure are antigen-binding fragments comprising any combination of the variable region(s) and the hinge region, CH1, CH2, CH3, and CL domains. In some embodiments, the anti-CTLA4 antibody or antigen-binding fragment thereof is human, murine (e.g., mouse and rat), donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken.

[0154] The anti-CTLA4 antibodies of the present disclosure may be monospecific, bispecific, trispecific, or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of CTLA4, or may be specific for both CTLA4 and heterologous proteins. See, e.g., PCT Publications WO93 / 17715; WO92 / 08802; WO91 / 00360; WO92 / 05793; Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., 1992, J. Immunol. 148:1547-1553.

[0155] The anti-CTLA4 antibodies of the present disclosure can be described or specified in terms of the particular CDRs they contain.The exact amino acid sequence boundaries of a given CDR or FR can be determined using the Kabat numbering scheme (Kabat et al., 1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD; Al-Lazikani et al., (1997) JMB 273, 927-948 (Chothia numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745 (Contact numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol., 2003 Jan;27(1):55-77 (the "IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol,2001 Jun 8;309(3):657-70, (the "Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS,1989,86(23):9268-9272 (the "AbM" numbering scheme). The boundaries of a given CDR may vary depending on the scheme used to identify it. In some embodiments, the "CDR" or "complementarity determining region" of a given antibody or region thereof (e.g., its variable region), or each specific CDR (e.g., CDR-H1, CDR-H2, CDR-H3), will be understood to encompass one (or a specific) CDR defined by any of the above schemes. For example, if a specific CDR (e.g., CDR-H3) is located within a given V H or V L When a region amino acid sequence is described as containing the amino acid sequence of a corresponding CDR, it is understood that such CDR has the sequence of the corresponding CDR (e.g., CDR-H3) in the variable region defined by any of the above schemes. Schemes for identifying a particular CDR or multiple particular CDRs can be designated as CDRs defined by the Kabat, Chothia, AbM, or IMGT methods.

[0156] In some embodiments, the numbering of amino acid residues in the CDR sequences of the anti-CTLA4 antibodies or antigen-binding fragments thereof provided herein is according to the IMGT numbering scheme described in Lefranc, MP et al., Dev. Comp. Immunol., 2003, 27, 55-77.

[0157] In some embodiments, the anti-CTLA4 antibody of the present disclosure comprises the CDRs of the ipilimumab antibody. In some embodiments, the CDRs of the ipilimumab antibody are described using the Kabat numbering scheme (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NTH Publication No. 91-3242). The present disclosure encompasses an anti-CTLA4 antibody or derivative thereof comprising a heavy or light chain variable domain, the variable domain comprising (a) a set of three CDRs derived from the monoclonal antibody ipilimumab, and (b) a set of four framework regions, the set of framework regions being different from the set of framework regions of the monoclonal antibody ipilimumab, and the anti-CTLA4 antibody or derivative thereof binds to CTLA4. In certain embodiments, the anti-CTLA4 antibody is ipilimumab. The antibody ipilimumab is also known as YERVOY®.

[0158] In some embodiments, the anti-CTLA4 antibody is a monoclonal antibody.

[0159] Anti-CTLA4 antibodies of the invention can also be described or specified in terms of their binding affinity to CTLA4 (e.g., human CTLA4). Preferred binding affinities include those with a binding affinity of 5×10 -2 M, 10 -2 M, 5 x 10 -3 M, 10 -3 M, 5 x 10 -4 M, 10 -4 M, 5 x 10 -5 M, 10 -5 M, 5 x 10 -6 M, 10 -6 M, 5 x 10 -7 M, 10 -7 M, 5 x 10 -8 M, 10 -8 M, 5 x 10-9 M, 10 -9 M, 5 x 10 -10 M, 10 -10 M, 5 x 10 -11 M, 10 -11 M, 5 x 10 -12 M, 10 -12 M, 5 x 10 -13 M, 10 -13 M, 5 x 10 -14 M, 10 -14 M, 5 x 10 -15 M, or 10 -15 Those with a dissociation constant or Kd less than M are included.

[0160] There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with a heavy chain designated α, δ, ε, γ, and μ. The γ and α classes are further divided into subclasses; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. IgG1 antibodies can exist in multiple polymorphic variants called allotypes (reviewed in Jefferis and Lefranc 2009. mAbs Vol 1 Issue 4 1-7), any of which are suitable for use in some of the embodiments herein. Common allotypic variants in the human population are designated by the letters a, f, n, z, or combinations thereof. In any of the embodiments herein, the antibody can comprise a heavy chain Fc region comprising a human IgG Fc region. In a further embodiment, the human IgG Fc region comprises human IgG1.

[0161] Antibodies also include modified derivatives, i.e., derivatives modified such that any type of molecule is covalently attached to the antibody such that the covalent attachment does not inhibit the antibody's binding to CTLA4. For example, but not limited to, antibody derivatives include antibodies modified by, e.g., glycosylation, acetylation, PEGylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Furthermore, derivatives may contain one or more atypical amino acids.

[0162] The anti-CTLA4 antibodies or antigen-binding fragments thereof described herein can be administered by any suitable route and manner. Suitable routes for administering the antibodies or antigen-binding fragments thereof of the present invention are well known in the art and can be selected by those skilled in the art. In one embodiment, the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein are administered parenterally. Parenteral administration refers to a mode of administration other than enteral or topical administration, usually by injection, and includes intraepidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, intracranial, intrathoracic, epidural, and intrasternal injection and infusion. In some embodiments, the route of administration of the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein is intravenous infusion. In some embodiments, the route of administration of the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein is intravenous injection or infusion. In some embodiments, the route of administration of the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein is oral.

[0163] F. Nucleic Acids, Host Cells and Methods of Production In some embodiments, also provided herein are nucleic acids encoding the anti-PD-1 antibodies or antigen-binding fragments thereof described herein, the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein, or the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein. Further provided herein are vectors comprising a nucleic acid encoding the anti-PD-1 antibodies or antigen-binding fragments thereof described herein, the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein, or the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein. Further provided herein are host cells expressing a nucleic acid encoding the anti-PD-1 antibodies or antigen-binding fragments thereof described herein, the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein, or the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein. Further provided herein are host cells comprising a vector comprising a nucleic acid encoding the anti-PD-1 antibodies or antigen-binding fragments thereof described herein, the anti-PD-L1 antibodies or antigen-binding fragments thereof described herein, or the anti-CTLA4 antibodies or antigen-binding fragments thereof described herein.

[0164] The anti-PD-1 antibodies described herein, the anti-PD-L1 antibodies described herein, or the anti-CTLA4 antibodies described herein can be prepared by well-known recombinant techniques using well-known expression vector systems and host cells. In one embodiment, the antibodies are prepared in CHO cells using the GS expression vector system disclosed in De la Cruz Edmunds et al., 2006, Molecular Biotechnology 34;179-190, EP 216846, U.S. Patent No. 5,981,216, WO 87 / 04462, EP 323997, U.S. Patent No. 5,591,639, U.S. Patent No. 5,658,759, EP 338841, U.S. Patent No. 5,879,936, and U.S. Patent No. 5,891,693.

[0165] The anti-PD-1 antibodies, anti-PD-L1 antibodies, or anti-CTLA4 antibodies described herein that are monoclonal may be produced by, for example, the hybridoma method first described by Kohler et al., Nature, 256, 495 (1975), or by recombinant DNA methods. Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described, for example, in Clackson et al., Nature, 352, 624-628 (1991) and Marks et al., J. Mol. Biol., 222(3):581-597 (1991). Monoclonal antibodies may be obtained from any suitable source. Thus, for example, monoclonal antibodies may be obtained from hybridomas prepared from mouse splenic B cells obtained from mice immunized with an antigen of interest, e.g., in the form of cells expressing the antigen on their surface or nucleic acid encoding the antigen of interest. Monoclonal antibodies can also be obtained from hybridomas derived from antibody-expressing cells of immunized humans or non-human mammals, such as rats, dogs, or primates.

[0166] In one embodiment, an antibody of the invention (e.g., an anti-PD-1 antibody, anti-PD-L1 antibody, or anti-CTLA4 antibody) is a human antibody. Human monoclonal antibodies against PD-1, PD-L1, or CTLA4 may be generated using transgenic or transchromosomic mice carrying parts of the human immune system, rather than the mouse system. Such transgenic and transchromosomic mice include those referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as "transgenic mice."

[0167] HuMAb mice contain human immunoglobulin gene minilocuses encoding unrearranged human heavy (μ and γ) and κ light chain immunoglobulin sequences, along with targeted mutations that inactivate the endogenous μ and κ chain loci (Lonberg, N. et al., Nature, 368, 856-859 (1994)). Accordingly, these mice exhibit reduced expression of mouse IgM or κ, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation, resulting in the generation of high-affinity human IgG and κ monoclonal antibodies (Lonberg, N. et al. (1994), supra; reviewed in Lonberg, N. Handbook of Experimental Pharmacology 113, 49-101 (1994), Lonberg, N. and Huszar, D., Intern. Rev. Immunol, Vol. 13, 65-93 (1995), and Harding, F. and Lonberg, N. Ann, NY Acad. Sci 764:536-546 (1995)). The generation of HuMAb mice is described in detail in Taylor, L. et al., Nucleic Acids Research. 20:6287-6295 (1992), Chen, J. et al., International Immunology. 5:647-656 (1993), Tuaillon et al., J. Immunol. 152:2912-2920 (1994), Taylor, L. et al., International Immunology, 6:579-591 (1994), and Fishwild, D. et al., Nature Biotechnology, 14:845-851 (1996). See also U.S. Pat. Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,789,650, 5,877,397, 5,661,016, 5,814,318, 5,874,299, 5,770,429, 5,545,807, WO 98 / 24884, WO 94 / 25585, WO 93 / 1227, WO 92 / 22645, WO 92 / 03918, and WO 01 / 09187.

[0168] The HCo7 mouse has a JKD disruption of the endogenous light chain (kappa) gene (as described in Chen et al., EMBO J. 12:821-830 (1993)), a CMD disruption of the endogenous heavy chain gene (as described in Example 1 of WO01 / 14424), a KCo5 human kappa light chain transgene (as described in Fishwild et al., Nature Biotechnology, 14:845-851 (1996)), and an HCo7 human heavy chain transgene (as described in U.S. Patent No. 5,770,429).

[0169] HCo12 mice have a JKD disruption of the endogenous light chain (kappa) gene (as described in Chen et al., EMBO J. 12:821-830 (1993)), a CMD disruption of the endogenous heavy chain gene (as described in Example 1 of WO01 / 14424), a KCo5 human kappa light chain transgene (as described in Fishwild et al., Nature Biotechnology, 14:845-851 (1996)), and an HCo12 human heavy chain transgene (as described in Example 2 of WO01 / 14424).

[0170] The HCo17 transgenic mouse strain (see also US2010 / 0077497) was generated by co-injection of an 80 kb pHC2 insert (Taylor et al. (1994) Int. Immunol., 6:579-591), a 20 kb pVX6 insert, and a -460 kb yeast artificial chromosome fragment of the yIgH24 chromosome. This strain was designated (HCo17)25950. The (HCo17)25950 strain was then crossed with mice containing the CMD mutation (described in Example 1 of PCT Publication WO01109187), the JKD mutation (Chen et al. (1993) EMBO J. 12:811-820), and the (KC05)9272 transgene (Fishwild et al. (1996) Nature Biotechnology, 14:845-851). The resulting mice express human immunoglobulin heavy and kappa light chain transgenes in a homozygous background in which the endogenous mouse heavy and kappa light chain loci are disrupted.

[0171] The HCo20 transgenic mouse strain was the result of co-injection of the minilocus 30 heavy chain transgene pHC2, the YAC yIgH10 containing the germline variable region (Vh), and the minilocus construct pVx6 (described in WO09097006). The (HCo20) strain was then crossed with mice containing the CMD mutation (described in Example 1 of PCT Publication 01 / 09187), the JKD mutation (Chen et al., (1993) EMBO J. 12:811-820), and the (KCO5)9272 transgene ((Fishwild et al., (1996) Nature Biotechnology, 14:845-851). The resulting mice express human 10 immunoglobulin heavy and kappa light chain transgenes in a homozygous background in which the endogenous mouse heavy and kappa light chain loci are disrupted.

[0172] To generate HuMab mice with the beneficial effects of the Balb / c strain, HuMab mice were crossed with KCO05[MIK] (Balb) mice, which were generated by backcrossing the KC05 strain (as described in Fishwild et al. (1996) Nature Biotechnology, 14:845-851) with wild-type Balb / c mice, to generate mice as described in WO 09097006. This cross was used to generate Balb / c hybrids of the HCo12, HCo17, and HCo20 strains.

[0173] In the KM mouse strain, the endogenous mouse kappa light chain gene is homozygously disrupted as described in Chen et al., EMBO J. 12:811-820 (1993), and the endogenous mouse heavy chain gene is homozygously disrupted as described in Example 1 of WO01 / 09187. This mouse strain harbors a human kappa light chain transgene, KCo5, as described in Fishwild et al., Nature Biotechnology, 14:845-851 (1996). This mouse strain also harbors a human heavy chain transchromosome consisting of chromosome 14 fragment hCF(SC20), as described in WO02 / 43478.

[0174] Splenocytes from these transgenic mice can be used to produce hybridomas secreting human monoclonal antibodies according to known techniques. Human monoclonal or polyclonal antibodies of the invention, or antibodies of the invention derived from other species, can also be produced transgenically by generating another non-human mammal or plant transgenic for the desired immunoglobulin heavy and light chain sequences and producing the antibody therefrom in a recoverable form. For transgenic production in mammals, antibodies can be produced in goats, cows, or other mammals and recovered from their milk. See, e.g., U.S. Pat. Nos. 5,827,690, 5,756,687, 5,750,172, and 5,741,957.

[0175] Furthermore, human antibodies of the present invention or antibodies of the present invention derived from other species can be generated by display-type techniques using techniques well known in the art, including, but not limited to, phage display, retroviral display, ribosome display, and other techniques, and the resulting molecules can be subjected to further maturation, such as affinity maturation, which techniques are well known in the art (e.g., Hoogenboom et al., J. Mol. Biol. 227(2):381-388 (1992) (phage display); Vaughan et al., Nature Biotech. 14:309 (1996) (phage display); Hanes and Plucthau, PNAS USA 94:4937-4942 (1997) (ribosome display); Parmley and Smith, Gene, 73:305-318 (1988) (phage display); Scott, TIBS. 17:241-245 (1992); Cwirla et al. (See, for example, Russel et al., PNAS USA, 87:6378-6382 (1990); Russell et al., Nucl. Acids Research, 21:1081-4085 (1993); Hogenboom et al., Immunol. Reviews, 130:43-68 (1992); Chiswell and McCafferty, TIBTECH, 10:80-84 (1992); and U.S. Patent No. 5,733,743.) When display techniques are used to generate antibodies that are not non-human, such antibodies may be humanized.

[0176] G. Treatment Results In some embodiments, treating a subject comprises inhibiting the growth of cancer cells, inhibiting the proliferation of cancer cells, inhibiting the migration of cancer cells, inhibiting the invasion of cancer cells, reducing or eliminating one or more signs or symptoms of cancer, reducing the size (e.g., volume) of a cancer tumor, reducing the number of cancer tumors, reducing the number of cancer cells, inducing necrosis, pyroptosis, oncosis, apoptosis, autophagy, or other cell death in cancer cells, increasing the survival of the subject, or enhancing the therapeutic effect of another drug or therapy.

[0177] In some embodiments, treating a subject as described herein results in a tumor growth inhibition (TGI) index of between about 10% and 70% (e.g., about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70%). Preferably, treating a subject results in a TGI index of at least about 70% (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%). More preferably, treating a subject results in a TGI index of at least about 85% (e.g., about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%). Even more preferably, treating a subject results in a TGI index of at least about 95% (e.g., about 95%, 96%, 97%, 98%, 99%, or 100%). Most preferably, treating a subject results in a TGI index of about 100% or greater (e.g., about 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 125%, 130%, 135%, 140%, 145%, 150% or greater).

[0178] In certain embodiments, treating a subject with tucatinib, or a salt or solvate thereof, and an anti-PD-1 antibody, or antigen-binding fragment thereof, results in a TGI index that is greater than that observed when tucatinib, or a salt or solvate thereof, or the anti-PD-1 antibody, or antigen-binding fragment thereof, is used alone. In some cases, treating a subject results in a TGI index that is greater than that observed when tucatinib, or a salt or solvate thereof, or the anti-PD-1 antibody, or antigen-binding fragment thereof, is used alone. In other cases, treating a subject results in a TGI index that is greater than that observed when the anti-PD-1 antibody, or antigen-binding fragment thereof, is used alone. In some embodiments, treating a subject results in a TGI index that is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% greater than that observed when tucatinib or a salt or solvate thereof, or the anti-PD-1 antibody or antigen-binding fragment thereof is used alone.

[0179] In certain embodiments, treating a subject with tucatinib, or a salt or solvate thereof, and an anti-PD-L1 antibody, or antigen-binding fragment thereof, results in a TGI index that is greater than that observed when tucatinib, or a salt or solvate thereof, or the anti-PD-L1 antibody, or antigen-binding fragment thereof, is used alone. In some cases, treating a subject results in a TGI index that is greater than that observed when tucatinib, or a salt or solvate thereof, or the anti-PD-L1 antibody, or antigen-binding fragment thereof, is used alone. In other cases, treating a subject results in a TGI index that is greater than that observed when the anti-PD-L1 antibody, or antigen-binding fragment thereof, is used alone. In some embodiments, treating a subject results in a TGI index that is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% greater than that observed when using tucatinib or a salt or solvate thereof, or the anti-PD-L1 antibody or antigen-binding fragment thereof alone.

[0180] In some embodiments, the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody, or antigen-binding fragment thereof, is synergistic. In certain embodiments, with respect to a synergistic combination, treating a subject results in a TGI index that is greater than that expected if the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody, or antigen-binding fragment thereof, results in an additive effect. In some cases, the TGI index observed when administering a combination of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody, or antigen-binding fragment thereof, is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% greater than the TGI index expected when the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-1 antibody, or antigen-binding fragment thereof, results in an additive effect.

[0181] In some embodiments, the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody, or antigen-binding fragment thereof, is synergistic. In certain embodiments, a synergistic combination results in a TGI index that is greater than that expected if the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody, or antigen-binding fragment thereof, results in an additive effect. In some cases, the TGI index observed when administering the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody, or antigen-binding fragment thereof, is at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% greater than the TGI index that would be expected if the combination of tucatinib, or a salt or solvate thereof, and the anti-PD-L1 antibody, or antigen-binding fragment thereof, resulted in an additive effect.

[0182] In one aspect, the methods of treating cancer with tucatinib described herein and anti-PD-1 antibodies described herein result in an improvement in one or more therapeutic effects compared to baseline in a subject following administration of tucatinib described herein and anti-PD-1 antibodies described herein. In some embodiments, the one or more therapeutic effects are tumor size from a solid tumor, objective response rate, duration of response, time to response, progression-free survival, overall survival, or any combination thereof. In one embodiment, the one or more therapeutic effects are tumor size from a solid tumor. In one embodiment, the one or more therapeutic effects are a reduction in tumor size. In one embodiment, the one or more therapeutic effects are stable disease. In one embodiment, the one or more therapeutic effects are partial responses. In one embodiment, the one or more therapeutic effects are complete responses. In one embodiment, the one or more therapeutic effects are objective response rates. In one embodiment, the one or more therapeutic effects are duration of response. In one embodiment, the one or more therapeutic effects are time to response. In one embodiment, the one or more therapeutic effects are progression-free survival. In one embodiment, the one or more therapeutic benefits is overall survival. In one embodiment, the one or more therapeutic benefits is cancer regression.

[0183] In one embodiment of the methods or uses or products for use provided herein, response to treatment with tucatinib described herein and anti-PD-1 antibodies described herein may include the following criteria (RECIST criteria 1.1): [Table 1]

[0184] In one embodiment of the methods or uses or products for use provided herein, the efficacy of treatment with tucatinib described herein and the anti-PD-1 antibodies described herein is assessed by measuring the objective response rate. In some embodiments, the objective response rate is the percentage of patients experiencing a reduction in tumor size by a predefined amount over a minimum period of time. In some embodiments, the objective response rate is based on RECIST v1.1. In one embodiment, the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In one embodiment, the objective response rate is at least about 20% to 80%. In one embodiment, the objective response rate is at least about 30% to 80%. In one embodiment, the objective response rate is at least about 40% to 80%. In one embodiment, the objective response rate is at least about 50% to 80%. In one embodiment, the objective response rate is at least about 60% to 80%. In one embodiment, the objective response rate is at least about 70% to 80%. In one embodiment, the objective response rate is at least about 80%. In one embodiment, the objective response rate is at least about 85%. In one embodiment, the objective response rate is at least about 90%. In one embodiment, the objective response rate is at least about 95%. In one embodiment, the objective response rate is at least about 98%. In one embodiment, the objective response rate is at least about 99%. In one embodiment, the objective response rate is at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80%. In one embodiment, the objective response rate is at least 20% to 80%. In one embodiment, the objective response rate is at least 30% to 80%. In one embodiment, the objective response rate is at least 40% to 80%. In one embodiment, the objective response rate is at least 50% to 80%. In one embodiment, the objective response rate is at least 60% to 80%. In one embodiment, the objective response rate is at least 70% to 80%. In one embodiment, the objective response rate is at least 80%. In one embodiment, the objective response rate is at least 85%. In one embodiment, the objective response rate is at least 90%. In one embodiment, the objective response rate is at least 95%. In one embodiment, the objective response rate is at least 98%. In one embodiment, the objective response rate is at least 99%. In one embodiment, the objective response rate is at least 100%.

[0185] In one embodiment of the methods or uses or products for use provided herein, response to treatment with tucatinib described herein and anti-PD-1 antibodies described herein is assessed by measuring the size of a tumor derived from a cancer (e.g., a solid tumor) described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of the tumor derived from the cancer prior to administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10%-80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 20% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 30% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 40% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 50% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 60% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 70% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 85%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 90%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 95%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 98%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 99%. In one embodiment, the size of a tumor derived from the cancer is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80% compared to the size of a tumor derived from the cancer before administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In one embodiment, the size of a tumor derived from the cancer is reduced by at least 10% to 80%. In one embodiment, the size of a tumor derived from the cancer is reduced by at least 20% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 30% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 40% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 50% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 60% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 70% to 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 80%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 85%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 90%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 95%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 98%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 99%. In one embodiment, the size of the cancer-derived tumor is reduced by 100%. In one embodiment, the size of the cancer-derived tumor is measured by magnetic resonance imaging (MRI). In one embodiment, the size of the cancer-derived tumor is measured by computed tomography (CT). In one embodiment, the size of a cancer-derived tumor is measured by positron emission tomography (PET). In one embodiment, the size of a cancer-derived tumor is measured by mammography. In one embodiment, the size of a cancer-derived tumor is measured by ultrasound examination. See Gruber et al., 2013, BMC Cancer. 13:328.

[0186] In one embodiment of the methods or uses or products for use provided and described herein, the response to treatment with tucatinib described herein and an anti-PD-1 antibody described herein promotes regression of a tumor derived from a cancer (e.g., a solid tumor) described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of the tumor derived from the cancer prior to administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In one embodiment, the tumor derived from cancer regresses by at least about 10% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 20% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 30% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 40% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 50% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 60% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 70% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 85%. In one embodiment, the tumor derived from cancer regresses by at least about 90%. In one embodiment, the tumor derived from cancer regresses by at least about 95%. In one embodiment, the tumor derived from cancer regresses by at least about 98%. In one embodiment, the tumor derived from the cancer shrinks by at least about 99%. In one embodiment, the tumor derived from the cancer shrinks by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80% compared to the size of the tumor derived from the cancer before administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In one embodiment, the tumor derived from cancer regresses by at least 10% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 20% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 30% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 40% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 50% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 60% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 70% to 80%. In one embodiment, the tumor derived from cancer regresses by at least 80%. In one embodiment, the tumor derived from cancer regresses by at least 85%. In one embodiment, the tumor derived from cancer regresses by at least 90%. In one embodiment, the tumor derived from cancer regresses by at least 95%. In one embodiment, the tumor derived from cancer regresses by at least 98%. In one embodiment, the tumor derived from cancer regresses by at least 99%. In one embodiment, the tumor resulting from the cancer undergoes 100% regression. In one embodiment, tumor regression is determined by magnetic resonance imaging (MRI). In one embodiment, tumor regression is determined by computed tomography (CT). In one embodiment, tumor regression is determined by positron emission tomography (PET). In one embodiment, tumor regression is determined by mammography. In one embodiment, tumor regression is determined by ultrasound. See Gruber et al., 2013, BMC Cancer. 13:328.

[0187] In one embodiment of the methods or uses or products for use described herein, response to treatment with the described tucatinib and anti-PD-1 antibodies described herein is assessed by measuring the time to progression-free survival after administration of the described tucatinib and / or anti-PD-1 antibodies described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of the described tucatinib and / or anti-PD-1 antibodies described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 6 months after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 1 year after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 2 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 3 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 4 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 5 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 2 years, at least 3 years, at least 4 years, or at least 5 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 6 months after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 1 year after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 2 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 3 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 4 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 5 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein.

[0188] In one embodiment of the methods or uses or products for use described herein, response to treatment with tucatinib described herein and anti-PD-1 antibodies described herein is assessed by measuring the time to overall survival after administration of tucatinib described herein and / or anti-PD-1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib described herein and / or anti-PD-1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 6 months after administration of tucatinib described herein and / or anti-PD-1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 1 year after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 2 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 3 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 4 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 5 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least about 12 months, at least 18 months, at least 2 years, at least 3 years, at least 4 years, or at least 5 years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least 6 months after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least one year after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least two years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least three years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least four years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least five years after administration of tucatinib described herein and / or an anti-PD-1 antibody described herein.

[0189] In one embodiment of the methods or uses or products for use described herein, response to treatment with tucatinib described herein and the anti-PD-1 antibodies described herein is assessed by measuring the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 6 months after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 1 year after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 2 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 3 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 4 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least about 5 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least two years, at least 3 years, at least 4 years, or at least 5 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 6 months after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 1 year after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 2 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 3 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 4 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-1 antibodies described herein is at least 5 years after administration of tucatinib described herein and / or the anti-PD-1 antibodies described herein.

[0190] In one aspect, the methods of treating cancer with tucatinib described herein and anti-PD-L1 antibodies described herein result in an improvement in one or more therapeutic effects compared to baseline in a subject following administration of tucatinib described herein and anti-PD-L1 antibodies described herein. In some embodiments, the one or more therapeutic effects are tumor size from a solid tumor, objective response rate, duration of response, time to response, progression-free survival, overall survival, or any combination thereof. In one embodiment, the one or more therapeutic effects are tumor size from a solid tumor. In one embodiment, the one or more therapeutic effects are a reduction in tumor size. In one embodiment, the one or more therapeutic effects are stable disease. In one embodiment, the one or more therapeutic effects are partial responses. In one embodiment, the one or more therapeutic effects are complete responses. In one embodiment, the one or more therapeutic effects are objective response rates. In one embodiment, the one or more therapeutic effects are duration of response. In one embodiment, the one or more therapeutic effects are time to response. In one embodiment, the one or more therapeutic effects are progression-free survival. In one embodiment, the one or more therapeutic benefits is overall survival. In one embodiment, the one or more therapeutic benefits is cancer regression.

[0191] In one embodiment of the methods or uses or products for use provided herein, response to treatment with tucatinib described herein and anti-PD-L1 antibodies described herein may include the following criteria (RECIST criteria 1.1): [Table 2]

[0192] In one embodiment of the methods or uses or products for use provided herein, the efficacy of treatment with tucatinib described herein and anti-PD-L1 antibodies described herein is assessed by measuring the objective response rate. In some embodiments, the objective response rate is the percentage of patients experiencing a reduction in tumor size by a predefined amount over a minimum period of time. In some embodiments, the objective response rate is based on RECIST v1.1. In one embodiment, the objective response rate is at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80%. In one embodiment, the objective response rate is at least about 20% to 80%. In one embodiment, the objective response rate is at least about 30% to 80%. In one embodiment, the objective response rate is at least about 40% to 80%. In one embodiment, the objective response rate is at least about 50% to 80%. In one embodiment, the objective response rate is at least about 60% to 80%. In one embodiment, the objective response rate is at least about 70% to 80%. In one embodiment, the objective response rate is at least about 80%. In one embodiment, the objective response rate is at least about 85%. In one embodiment, the objective response rate is at least about 90%. In one embodiment, the objective response rate is at least about 95%. In one embodiment, the objective response rate is at least about 98%. In one embodiment, the objective response rate is at least about 99%. In one embodiment, the objective response rate is at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80%. In one embodiment, the objective response rate is at least 20% to 80%. In one embodiment, the objective response rate is at least 30% to 80%. In one embodiment, the objective response rate is at least 40% to 80%. In one embodiment, the objective response rate is at least 50% to 80%. In one embodiment, the objective response rate is at least 60% to 80%. In one embodiment, the objective response rate is at least 70% to 80%. In one embodiment, the objective response rate is at least 80%. In one embodiment, the objective response rate is at least 85%. In one embodiment, the objective response rate is at least 90%. In one embodiment, the objective response rate is at least 95%. In one embodiment, the objective response rate is at least 98%. In one embodiment, the objective response rate is at least 99%. In one embodiment, the objective response rate is at least 100%.

[0193] In one embodiment of the methods or uses or products for use provided herein, response to treatment with tucatinib described herein and anti-PD-L1 antibodies described herein is assessed by measuring the size of a tumor derived from a cancer (e.g., a solid tumor) described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of the tumor derived from the cancer prior to administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10% to 80%. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 20% to 80%. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 30% to 80%. In one embodiment, the size of a tumor derived from the cancer is reduced by at least about 40% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 50% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 60% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 70% to 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 80%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 85%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 90%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 95%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 98%. In one embodiment, the size of a tumor derived from a cancer is reduced by at least about 99%. In one embodiment, the size of a tumor derived from the cancer is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80% compared to the size of a tumor derived from the cancer before administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In one embodiment, the size of a tumor derived from cancer is reduced by at least 10% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 20% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 30% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 40% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 50% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 60% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 70% to 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 80%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 85%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 90%. In one embodiment, the size of a tumor derived from cancer is reduced by at least 95%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 98%. In one embodiment, the size of the cancer-derived tumor is reduced by at least 99%. In one embodiment, the size of the cancer-derived tumor is reduced by 100%. In one embodiment, the size of the cancer-derived tumor is measured by magnetic resonance imaging (MRI). In one embodiment, the size of the cancer-derived tumor is measured by computed tomography (CT). In one embodiment, the size of the cancer-derived tumor is measured by positron emission tomography (PET). In one embodiment, the size of the cancer-derived tumor is measured by mammography. In one embodiment, the size of the cancer-derived tumor is measured by ultrasound. See Gruber et al., 2013, BMC Cancer. 13:328.

[0194] In one embodiment of the methods or uses or products for use provided and described herein, the response to treatment with tucatinib described herein and an anti-PD-L1 antibody described herein promotes regression of a tumor derived from a cancer (e.g., a solid tumor) described herein. In one embodiment, the size of the tumor derived from the cancer is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the size of the tumor derived from the cancer prior to administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In one embodiment, the tumor derived from the cancer regresses by at least about 10% to about 80%. In one embodiment, the tumor derived from the cancer regresses by at least about 20% to about 80%. In one embodiment, the tumor derived from the cancer regresses by at least about 30% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 40% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 50% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 60% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 70% to about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 80%. In one embodiment, the tumor derived from cancer regresses by at least about 85%. In one embodiment, the tumor derived from cancer regresses by at least about 90%. In one embodiment, the tumor derived from cancer regresses by at least about 95%. In one embodiment, the tumor derived from cancer regresses by at least about 98%. In one embodiment, the tumor derived from cancer regresses by at least about 99%. In one embodiment, the tumor derived from the cancer shrinks by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, or at least 80% compared to the size of the tumor derived from the cancer before administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In one embodiment, the tumor derived from the cancer shrinks by at least 10% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 20% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 30% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 40% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 50% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 60% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 70% to 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 80%. In one embodiment, the tumor derived from the cancer shrinks by at least 85%. In one embodiment, the tumor derived from the cancer shrinks by at least 90%. In one embodiment, the tumor derived from the cancer shrinks by at least 95%. In one embodiment, the tumor derived from the cancer shrinks by at least 98%. In one embodiment, the tumor derived from the cancer shrinks by at least 99%. In one embodiment, the tumor derived from the cancer shrinks by 100%. In one embodiment, the tumor shrinkage is determined by magnetic resonance imaging (MRI). In one embodiment, the tumor shrinkage is determined by computed tomography (CT). In one embodiment, the tumor shrinkage is determined by positron emission tomography (PET). In one embodiment, the tumor shrinkage is determined by mammography. In one embodiment, the tumor shrinkage is determined by ultrasound. See Gruber et.al., 2013, BMC Cancer. 13:328.

[0195] In one embodiment of the methods or uses or products for use described herein, response to treatment with the described tucatinib and anti-PD-L1 antibodies described herein is assessed by measuring the time to progression-free survival after administration of the described tucatinib and / or anti-PD-L1 antibodies described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of the described tucatinib and / or anti-PD-L1 antibodies described herein. In some embodiments, the subject exhibits a progression-free survival of at least about 6 months after administration of the described tucatinib and / or anti-PD-L1 antibodies described herein. In some embodiments, a subject exhibits a progression-free survival of at least about 1 year after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least about 2 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least about 3 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least about 4 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least about 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 2 years, at least 3 years, at least 4 years, or at least 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least 6 months after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least 1 year after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits a progression-free survival of at least 2 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 3 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 4 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits a progression-free survival of at least 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein.

[0196] In one embodiment of the methods or uses or products for use described herein, response to treatment with tucatinib described herein and / or anti-PD-L1 antibodies described herein is assessed by measuring the time to overall survival after administration of tucatinib described herein and / or anti-PD-L1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib described herein and / or anti-PD-L1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 6 months after administration of tucatinib described herein and / or anti-PD-L1 antibodies described herein. In some embodiments, the subject exhibits an overall survival of at least about 1 year after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 2 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 3 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 4 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least about 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits an overall survival of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least about 12 months, at least 18 months, at least 2 years, at least 3 years, at least 4 years, or at least 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits an overall survival of at least 6 months after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits an overall survival of at least 1 year after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, a subject exhibits an overall survival of at least 2 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least 3 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein. In some embodiments, the subject exhibits an overall survival of at least 4 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein.In some embodiments, the subject exhibits an overall survival of at least 5 years after administration of tucatinib described herein and / or an anti-PD-L1 antibody described herein.

[0197] In one embodiment of the methods or uses or products for use described herein, response to treatment with tucatinib described herein and the anti-PD-L1 antibodies described herein is assessed by measuring the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 6 months following administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 1 year after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 2 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 3 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 4 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to the tucatinib described herein and the anti-PD-L1 antibodies described herein is at least about 5 years after administration of the tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to the tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least two years, at least 3 years, at least 4 years, or at least 5 years after administration of the tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 6 months after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 1 year after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 2 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 3 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 4 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein. In some embodiments, the duration of response to tucatinib described herein and the anti-PD-L1 antibodies described herein is at least 5 years after administration of tucatinib described herein and / or the anti-PD-L1 antibodies described herein.

[0198] H. Composition In another aspect, the present invention provides a pharmaceutical composition comprising tucatinib as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising an anti-PD-1 antibody as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising an anti-CTLA4 antibody as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising tucatinib as described herein, an anti-PD-1 antibody as described herein and a pharmaceutically acceptable carrier. In some embodiments, the anti-PD-1 antibody is a member selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, and CS1003. In some cases, the anti-PD-1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-CTLA4 antibody is ipilimumab.

[0199] In another aspect, the present invention provides a pharmaceutical composition comprising tucatinib as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising an anti-PD-L1 antibody as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising an anti-CTLA4 antibody as described herein and a pharmaceutically acceptable carrier. In another aspect, the present invention provides a pharmaceutical composition comprising tucatinib as described herein, an anti-PD-L1 antibody as described herein, and a pharmaceutically acceptable carrier. In some embodiments, the anti-PD-L1 antibody is a member selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, embafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333. In some cases, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-l1 antibody is BMS-936559. In some cases, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-l1 antibody is durvalumab. In some cases, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-l1 antibody is avelumab. In some embodiments, the anti-CTLA4 antibody is ipilimumab.

[0200] In some embodiments, the tucatinib described herein is present at a concentration of between 0.1 nM and 10 nM (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 nM). In other embodiments, the tucatinib described herein is present at a concentration of between about 10 nM and 100 nM (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nM). In some other embodiments, the tucatinib described herein is present at a concentration of between about 100 nM and 1,000 nM (e.g., about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1,000 nM).In still other embodiments, the tucatinib described herein has a cytotoxicity of at least about 1,000 nM to 10,000 nM (e.g., at least about 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 3,600, 3,700, 3,800, 4,900, 5,100, 5,100, 5,100, 5,100, 5,200, 5,200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 6,900, 7,100, 7,100, 7,200, 7,300, 7,400, 7,500, 8,600, 8,700, 8,800, 9,900, 10,100, 10,100, 11,100, 11,100, 12,100, 12,100, 13,100, 14,100, 14,100, 15,100, 15,100, 16,100, 16,100, 17,100, 18,100, 19,200, 21,200, 22,200, 23,200, 24,100 00, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000, 5,100 00, 5,200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500, 6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500, 7,600, 7,7 9,000, 9,100, 9,200, 9,300, 9,400, 9,500, 9,600, 9,700, 9,800, 9,900, 10,000 nM or more).

[0201] In some embodiments, the anti-PD-1 antibodies described herein are present at a concentration of between about 0.1 nM and 10 nM (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 nM). In other embodiments, the anti-PD-1 antibodies described herein are present at a concentration of between about 10 nM and 100 nM (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nM). In some other embodiments, the anti-PD-1 antibody is present at a concentration of between about 100 nM and 1,000 nM (e.g., about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1,000 nM).In yet other embodiments, the anti-PD-1 antibody has a concentration of at least about 1,000 nM to 10,000 nM (e.g., at least about 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 3,700, 3,800, 4,900, 5,100, 5,100, 5,100, 5,100, 5,200, 5,200, 5,300, 5,400, 5,500, 6,600, 6,700, 7,800, 8,900, 9,000, 10,100, 11,100, 12,100, 13,100, 14,100, 15,100, 16,100, 17,100, 18,100, 19,200, 20,210, 22,100, 23,100, 24,100, 25,100, 26,100, 27,100, 28,110, 29,210, 300, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 420 0, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5,200 00, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500, 6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500, 7,600, 7,700, 7, 800, 7,900, 8,000, 8,100, 8,200, 8,300, 8,400, 8,500, 8,600, 8,700, 8,800, 8,900, 9,000, 9,100, 9,200, 9,300, 9,400, 9,500, 9,600, 9,700, 9,800, 9,900, 10,000 nM or more).

[0202] In some embodiments, the anti-PD-L1 antibodies described herein are present at a concentration of between about 0.1 nM and 10 nM (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 nM). In other embodiments, the anti-PD-L1 antibodies described herein are present at a concentration of between about 10 nM and 100 nM (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nM). In some other embodiments, the anti-PD-L1 antibody is present at a concentration of between about 100 nM and 1,000 nM (e.g., about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1,000 nM).In yet other embodiments, the anti-PD-L1 antibody has a PD-L1 activity of at least about 1,000 nM to 10,000 nM (e.g., at least about 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 3,900, 3,100, 3,100, 3,110, 3,120, 3,130, 3,140, ​​3,150, 3,160, 3,170, 3,180, 3,200, 3,210, 3,220, 3,230, 3,240, 3,250, 3,300, 3,310, 3,320, 3,330, 3,340, 3,350, 3,360, 3,370, 3,410, 3,420, 3,430, 3,440, 3,450, 3,460, 3,470, 3,480, 3,510, 3,520, 3,530, 3,540, 3,550, 3,560, 3,570, 3,580, 3,600, 3,610, 3,620, 3,630, 3,640, 3,6 00, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5, 200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500, 6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500, 7,600, 7,700, 7 9,000, 9,100, 9,200, 9,300, 9,400, 9,500, 9,600, 9,700, 9,800, 9,900, 10,000 nM or more).

[0203] In some embodiments, the anti-CTLA4 antibodies described herein are present at a concentration of between about 0.1 nM and 10 nM (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 nM). In other embodiments, the anti-CTLA4 antibodies described herein are present at a concentration of between about 10 nM and 100 nM (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nM). In some other embodiments, the anti-CTLA4 antibody is present at a concentration of between about 100 nM and 1,000 nM (e.g., about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1,000 nM).In yet other embodiments, the anti-CTLA4 antibody has a concentration of at least about 1,000 nM to 10,000 nM (e.g., at least about 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 3,900, 3,100, 3,100, 3,110, 3,120, 3,130, 3,140, ​​3,150, 3,160, 3,170, 3,180, 3,200, 3,210, 3,220, 3,230, 3,240, 3,250, 3,300, 3,310, 3,320, 3,330, 3,340, 3,350, 3,360, 3,370, 3,410, 3,420, 3,430, 3,440, 3,450, 3,460, 3,470, 3,480, 3,510, 3,520, 3,530, 3,540, 3,550, 3,560, 3,570, 3,580, 3,600, 3,610, 3,620, 3,630, 3,640, 3,650, 3, 00, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5, 200, 5,300, 5,400, 5,500, 5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500, 6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500, 7,600, 7,700, 7 9,000, 9,100, 9,200, 9,300, 9,400, 9,500, 9,600, 9,700, 9,800, 9,900, 10,000 nM or more).

[0204] The pharmaceutical compositions of the present invention can be prepared by any method well known in the pharmaceutical field. Pharmaceutically acceptable carriers suitable for use in the present invention include any of the standard pharmaceutical carriers, buffers, and excipients, such as phosphate-buffered saline, water, and emulsions (such as oil / water or water / oil emulsions), as well as various types of wetting agents or adjuvants. Suitable pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, 19th ed. 1995). The preferred pharmaceutical carrier depends on the intended mode of administration of the active agent.

[0205] The pharmaceutical compositions of the present invention may comprise a combination of a drug (e.g., tucatinib described herein and / or an anti-PD-1 antibody described herein and / or an anti-PD-L1 antibody described herein and / or an anti-CTLA4 antibody described herein) as an active ingredient, or any pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. The pharmaceutical composition may optionally contain other therapeutic ingredients.

[0206] Compositions (e.g., comprising tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof) can be combined as an active ingredient in intimate admixture with a suitable pharmaceutical carrier or excipient according to conventional pharmaceutical compounding techniques. Any carrier or excipient suitable for the form of preparation desired for administration is contemplated for use with the compounds disclosed herein.

[0207] Pharmaceutical compositions include those suitable for oral, topical, parenteral, pulmonary, nasal, or rectal administration. The most suitable route of administration in any given case will depend on the nature and severity of the cancer condition, and optionally, on the HER2 status or stage of the cancer.

[0208] Other pharmaceutical compositions include those suitable for systemic (e.g., enteral or parenteral) administration. Systemic administration includes oral, rectal, sublingual, or sublabial administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other delivery modes include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. In certain embodiments, the pharmaceutical compositions of the present invention may be administered intratumorally.

[0209] Compositions for pulmonary administration include, but are not limited to, dry powder compositions consisting of a powder of a compound described herein (e.g., tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof), or a salt thereof, and a powder of a suitable carrier or lubricant. Compositions for pulmonary administration can be inhaled from any suitable dry powder inhaler device known to those of skill in the art.

[0210] Compositions for systemic administration include, but are not limited to, dry powder compositions consisting of a composition described herein (e.g., tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof) and a powder of a suitable carrier or excipient. Compositions for systemic administration can be presented as, but are not limited to, tablets, capsules, pills, syrups, liquids, and suspensions.

[0211] In some embodiments, the composition (e.g., tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof) further comprises a pharmaceutical surfactant. In other embodiments, the composition further comprises a cryoprotectant. In some embodiments, the cryoprotectant is selected from the group consisting of glucose, sucrose, trehalose, lactose, sodium glutamate, PVP, HPβCD, CD, glycerol, maltose, mannitol, and sucrose.

[0212] Pharmaceutical compositions or medicaments for use in the present invention can be formulated by standard techniques using one or more physiologically acceptable carriers or excipients. Suitable pharmaceutical carriers are described herein and in Remington: The Science and Practice of Pharmacy, 21st Ed., University of the Sciences in Philadelphia, Lippencott Williams & Wilkins (2005).

[0213] Parenteral controlled-release formulations of a composition (e.g., tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof) can be prepared as an implant, an oily injection, or as a particulate system. For an extensive review of delivery systems, see Banga, AJ, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Technomic Publishing Company, Inc., Lancaster, PA, (1995), which is incorporated herein by reference. Particulate systems include microspheres, microparticles, microcapsules, nanocapsules, nanospheres, and nanoparticles.

[0214] Polymers can be used for the ion-controlled release of the compositions of the present invention. Various degradable and non-degradable polymer matrices used for controlled drug delivery are known in the art (Langer R., Accounts Chem. Res., 26:537-542 (1993)). For example, the block copolymer Poloxamer 407 exists as a viscous, mobile liquid at low temperatures but forms a semi-solid gel at body temperature. This has been shown to be an effective vehicle for the formulation and sustained delivery of recombinant interleukin-2 and urease (Johnston et al., Pharm. Res., 9:425-434 (1992); and Pec et al., J. Parent. Sci. Tech., 44(2):58 65 (1990)). Alternatively, hydroxyapatite has been used as a microcarrier for the controlled release of proteins (Ijntema et al., Int. J. Pharm., 112:215-224 (1994)). In yet another embodiment, liposomes are used for controlled release and drug targeting of lipid-encapsulated drugs (Betageri et al., LIPOSOME DRUG DELIVERY SYSTEMS, Technomic Publishing Co., Inc., Lancaster, PA (1993)). Many additional systems for controlled delivery of therapeutic proteins are known. See, for example, U.S. Patent Nos. 5,055,303, 5,188,837, 4,235,871, 4,501,728, 4,837,028, 4,957,735, and 5,019,369, 5,055,303; 5,514,670; 5,413,797; 5,268,164; 5,004,697; 4,902,505; 5,506,206; 5,271,961; 5,254,342, and 5,534,496, each of which is incorporated herein by reference.

[0215] For oral administration of a combination of tucatinib described herein and / or an anti-PD-1 antibody described herein and / or an anti-PD-L1 antibody described herein and / or an anti-CTLA4 antibody described herein, the pharmaceutical composition or medicament may take the form of, for example, a tablet or capsule prepared by conventional means with pharmaceutically acceptable excipients. The present invention relates to a dry solid powder of tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof, or the drugs, in a pharmaceutical composition or medicament containing (a) a diluent or filler, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose (e.g., ethyl cellulose, microcrystalline cellulose), glycine, pectin, polyacrylate, or calcium hydrogen phosphate, calcium sulfate, (b) a lubricant, such as silica, talcum, stearic acid, magnesium or calcium salts, metal stearates, colloidal silicon dioxide, hydrogenated vegetable oil, corn denat. In the case of tablets, also (c) a binder, for example, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, or hydroxypropylmethylcellulose; optionally, (d) a disintegrating agent, for example, starch (e.g., potato starch or sodium starch), glycolate, agar, alginic acid or its sodium salt, or an effervescent mixture; (e) a wetting agent, for example, sodium lauryl sulfate, or (f) absorbents, colorants, flavors, and sweeteners.

[0216] Tablets can be either film-coated or enteric-coated according to methods known in the art.Liquid preparations for oral administration can be, for example, in the form of solutions, syrups, or suspensions, or can be presented as dry products that are reconstituted with water or other suitable vehicles before use.Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, such as suspending agents, for example, sorbitol syrup, cellulose derivatives, or hydrogenated edible oils and fats; emulsifiers, for example, lecithin or gum arabic; non-aqueous vehicles, for example, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, for example, methyl or propyl p-hydroxybenzoate or sorbic acid.Preparations can optionally contain buffer salts, flavoring agents, coloring agents, or sweeteners.If desired, preparations for oral administration can be suitably formulated to give controlled release of active compound(s).

[0217] Typical topical formulations of tucatinib described herein, anti-PD-1 antibodies described herein, anti-PD-L1 antibodies described herein, anti-CTLA4 antibodies described herein, or combinations thereof include creams, ointments, sprays, lotions, and patches. However, pharmaceutical compositions can be formulated for any type of administration, such as intradermal, subdermal, intravenous, intramuscular, subcutaneous, intranasal, intracerebral, intratracheal, intraarterial, intraperitoneal, intravesical, intrapleural, intracoronary, or intratumoral injection via syringe or other device. Formulations for administration by inhalation (e.g., aerosol), or oral or rectal administration are also contemplated.

[0218] The formulation suitable for transdermal application comprises an effective amount of one or more compounds described herein, optionally with a carrier.Preferred carriers include absorbable pharmacologically acceptable solvents that facilitate passage through the host's skin.For example, the transdermal device is in the form of a bandage, which comprises a backing material, a reservoir that contains the compound, optionally with a carrier, an optional rate-controlling barrier that delivers the compound to the host's skin at a controlled and predetermined rate over a long period of time, and a means for fixing the device to the skin.Matrix-type transdermal formulations can also be used.

[0219] The compositions and formulations described herein (e.g., tucatinib described herein, anti-PD-1 antibodies described herein, anti-PD-L1 antibodies described herein, anti-CTLA4 antibodies described herein, or combinations thereof) can be formulated for parenteral administration by injection, e.g., bolus injection or continuous infusion. Injectable formulations can be provided in unit dosage form, e.g., ampoules or multi-dose containers, with an added preservative. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are preferably prepared from fatty emulsions or suspensions. The compositions may be sterilized and may contain auxiliary agents such as preservatives, stabilizers, wetting or emulsifying agents, solubility enhancers, salts for adjusting osmotic pressure, or buffers. Alternatively, the active ingredient(s) may be in powder form to be reconstituted with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In addition, other therapeutically valuable substances may be contained. The compositions are prepared according to conventional mixing, granulating, or coating methods, respectively.

[0220] For administration by inhalation, compositions (e.g., comprising tucatinib described herein, anti-PD-1 antibodies described herein, anti-PD-L1 antibodies described herein, anti-CTLA4 antibodies described herein, or combinations thereof) can be conveniently delivered in the form of an aerosol spray from pressurized packs or nebulizers using a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges, e.g., gelatin capsules and cartridges for use in an inhaler or insufflator, can be formulated to contain a powder mix of the compound(s) and a suitable powder base, such as lactose or starch.

[0221] The compositions (e.g., comprising tucatinib described herein, an anti-PD-1 antibody described herein, an anti-PD-L1 antibody described herein, an anti-CTLA4 antibody described herein, or a combination thereof) can be formulated into rectal compositions, e.g., suppositories or retention enemas, e.g., containing conventional suppository bases, e.g., cocoa butter or other glycerides.

[0222] In addition, the active ingredient(s) can be formulated as a depot preparation. Such long-acting preparations can be administered by implantation (for example, subcutaneously or intramuscularly) or intramuscular injection. Thus, for example, one or more of the compounds described herein can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.

[0223] I. Manufactured Articles and Kits In another aspect, the invention provides an article of manufacture or kit for treating or ameliorating the effect of a solid tumor in a subject, wherein the article of manufacture or kit comprises a pharmaceutical composition of the invention (e.g., a pharmaceutical composition comprising tucatinib as described herein, an anti-PD-1 antibody as described herein, an anti-PD-L1 antibody as described herein, an anti-CTLA4 antibody as described herein, or a combination thereof). In some embodiments, the anti-PD-1 antibody is pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021, or CS1003. In some cases, the anti-PD-1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-PD-L1 antibody is atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, or BGB-A333. In some embodiments, the anti-PD-L1 antibody is atezolizumab. In some embodiments, the anti-PD-L1 antibody is BMS-936559. In some embodiments, the anti-PD-L1 antibody is durvalumab. In some embodiments, the anti-PD-L1 antibody is avelumab. In some cases, the anti-CTLA4 antibody is ipilimumab.

[0224] The article of manufacture or kit is suitable for treating or ameliorating the effects of cancer, particularly solid tumors. In some embodiments, the cancer is advanced cancer.

[0225] Materials and reagents for carrying out the various methods of the invention can be provided in articles of manufacture or kits to facilitate carrying out the methods. As used herein, the term "kit" includes a combination of items that facilitate a process, assay, analysis, or procedure. In particular, kits of the invention find utility in a wide range of applications, including, for example, diagnostics, prognoses, therapeutics, and the like.

[0226] The articles of manufacture or kits may contain not only chemical reagents but also other components. In addition, the articles of manufacture or kits of the present invention may include, but are not limited to, instructions for the user, devices and reagents for administering the combination of tucatinib and the anti-PD-1 antibody described herein or pharmaceutical compositions thereof, sample tubes, holders, trays, racks, dishes, plates, solutions, buffers, or other chemical reagents. In addition, the articles of manufacture or kits of the present invention may include, but are not limited to, instructions for the user, devices and reagents for administering the combination of tucatinib and the anti-PD-L1 antibody described herein or pharmaceutical compositions thereof, sample tubes, holders, trays, racks, dishes, plates, solutions, buffers, or other chemical reagents. In some embodiments, the articles of manufacture or kits include instructions, devices, or reagents for determining the genotype of a gene (e.g., HER2, KRAS, NRAS, BRAF) or determining the expression of HER2 in a sample. The articles of manufacture or kits of the present invention can be packaged, for example, in a box with a lid, for convenient storage and safe transport.

[0227] III. Binding and Other Assays In one embodiment, an antibody of the invention is tested for its antigen binding activity by known methods such as, for example, enzyme-linked immunosorbent assay (ELISA), immunoblotting (e.g., Western blot), flow cytometry (e.g., FACS™), immunohistochemistry, immunofluorescence, etc.

[0228] In another embodiment, a competition assay can be used to identify antibodies that compete with any one of the antibodies described herein for binding to PD-1, PD-L1, or CTLA4. Cross-competing antibodies can be readily identified based on their ability to cross-compete in standard PD-1, PD-L1, or CTLA4 binding assays, such as Biacore analysis, ELISA assays, or flow cytometry (see, e.g., WO 2013 / 173223). In certain embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) as any one of the antibodies disclosed herein. Details of exemplary methods for mapping antibody-binding epitopes are provided in Morris, "Epitope Mapping Protocols," in Methods in Molecular Biology, Vol. 66 (Humana Press, Totowa, NJ, 1996).

[0229] In an exemplary competitive assay, immobilized PD-1 is incubated in a solution containing a first, labeled antibody that binds to PD-1 and a second, unlabeled antibody to be tested for its ability to compete with the first antibody for binding to PD-1. The second antibody may be present in hybridoma supernatant. As a control, immobilized PD-1 is incubated in a solution containing the first, labeled antibody but not the second, unlabeled antibody. After incubation under conditions that allow binding of the first antibody to PD-1, excess unbound antibody is removed and the amount of label associated with immobilized PD-1 is measured. A substantial decrease in the amount of label associated with immobilized PD-1 in the test sample compared to the control sample indicates that the second antibody competes with the first antibody for binding to PD-1. See, e.g., Harlow et al., Antibodies: A Laboratory Manual. Ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988). In some embodiments, an anti-PD-1 antibody competes with another PD-1 antibody (e.g., pembrolizumab) for binding to PD-1 if the antibody inhibits the binding of the other antibody to PD-1 by more than 20%, more than 25%, more than 30%, more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% in a competition assay. In some embodiments, an anti-PD-1 antibody does not compete with another PD-1 antibody (e.g., pembrolizumab) for binding to PD-1 if the antibody inhibits the binding of the other antibody to PD-1 by less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% in a competition assay. In some embodiments, the PD-1 is human PD-1.

[0230] Similar competition assays can be performed to determine whether an anti-PD-L1 antibody competes with the anti-PD-L1 antibodies described herein for binding to PD-L1. In some embodiments, an anti-PD-L1 antibody competes with another PD-L1 antibody for binding to PD-L1 if the antibody inhibits binding of the other antibody to PD-L1 by more than 20%, more than 25%, more than 30%, more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% in a competition assay. In some embodiments, an anti-PD-L1 antibody does not compete for binding to PD-L1 with another PD-L1 antibody if the antibody inhibits the binding of the other antibody to PD-L1 by less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% in a competition assay. In some embodiments, the PD-L1 is human PD-L1.

[0231] Similar competition assays can be performed to determine whether an anti-CTLA4 antibody competes with an anti-CTLA4 antibody described herein for binding to CTLA4. In some embodiments, an anti-CTLA4 antibody competes with another CTLA4 antibody for binding to CTLA4 if the antibody inhibits binding of the other antibody to CTLA4 by more than 20%, more than 25%, more than 30%, more than 35%, more than 40%, more than 45%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95% in a competition assay. In some embodiments, an anti-CTLA4 antibody does not compete with another CTLA4 antibody for binding to CTLA4 if the antibody inhibits binding of the other antibody to CTLA4 by less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% in a competition assay. In some embodiments, the CTLA4 is human CTLA4.

[0232] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the present invention. The examples and embodiments described herein are for illustrative purposes only, and it is understood that various modifications or changes in light of them will occur to those skilled in the art and are within the spirit and scope of this application and the scope of the appended claims. [Example]

[0233] Example 1: Ex vivo effects of tucatinib on the tumor microenvironment This study was designed to evaluate the ex vivo effects of tucatinib on the tumor microenvironment using trastuzumab-sensitive and trastuzumab-resistant murine HER2-positive tumor models. The trastuzumab-sensitive model utilized female MMTV-Balb / c mice injected with H2N113 tumors via subcutaneous injection. The trastuzumab-resistant model utilized FVB mice implanted with Fo5 tumors as mammary fat pad transplants.

[0234] For the trastuzumab-resistant model, mice were treated with either vehicle control (0.5% methylcellulose) or tucatinib at 50 mg / kg orally once daily. Tumors were harvested 10–14 days after treatment with tucatinib at 50 mg / kg for Fo5 tumors and analyzed by FACS. As shown in Figure 1A and Figure 1B, tucatinib increased the infiltration of CD8+ T cells expressing PD-1 and IFNγ in the tumor. As shown in Figure 1C, tucatinib also increased the infiltration of CD8+ T cells expressing FOXP3 in the tumor. Finally, as shown in Figure 1D, tucatinib moderately increased the ratio of CD4+ to CD8+ T cells in the tumor.

[0235] For the trastuzumab-sensitive model, mice were treated with vehicle control (0.5% methylcellulose) or tucatinib at 100 mg / kg orally once daily. Tumors were harvested 14 days after treatment with tucatinib at 100 mg / kg for H2N113 tumors and analyzed by FACS. As shown in Figure 2A, tucatinib increased the infiltration of CD8+ T cells in tumors. As shown in Figures 2B and 2C, tucatinib increased the infiltration of CD4+ T cells that do not express FOXP3 and CD4+ T cells that express FOXP3 in tumors. As shown in Figures 2D–2H, tucatinib also increased the infiltration of CD8+ T cells expressing Ki67, IFNγ, PD-1, OX40, and TIM3 in tumors. As shown in Figure 2I, tucatinib also increased the infiltration of natural killer (NK) cells in tumors. As shown in Figure 2J, tucatinib reduced neutrophil infiltration in tumors. As shown in Figure 2K, tucatinib increased the percentage of CD11b dendritic cells in tumors. As shown in Figure 2L, tucatinib increased the percentage of MHC-II high and decreased the percentage of MHC-II low in tumors. These results suggest increased anti-tumor immunity after administration of tucatinib.

[0236] Example 2: Ex vivo effects of tucatinib on RNA expression profiles of tumor samples Trastuzumab-resistant Fo5 tumors were implanted, and mice were treated with vehicle control or tucatinib and harvested as described in Example 1. Harvested tumors were then processed for linear polyA RNA sequencing. As shown in Figures 3A and 3B, Fo5 tumors showed increased expression of genes predictive of response to immunotherapy, as indicated by the IFNγ gene expression signature (Figure 3A) and the expanded immune signature (Figure 3B). Columns represent individual tumor samples, and rows represent individual genes.

[0237] Example 3: In vivo effects of tucatinib on tumor growth and survival Trastuzumab-resistant Fo5 tumors were implanted as mammary fat pad explants in FVB mice. Mice were treated with vehicle control (0.5% methylcellulose), tucatinib (25 mg / kg, 50 mg / kg, or 100 mg / kg administered orally once daily), or a combination of anti-PD-1 antibody, anti-CTLA4, or isotype 2A3. Tucatinib significantly inhibited tumor growth in a dose-dependent manner, observed at 25 mg / kg, 50 mg / kg, and 100 mg / kg (p<0.05). Similar results were obtained in the H2N113 trastuzumab-sensitive tumor model. Furthermore, the combination of tucatinib at 50 mg / kg with PD-1 blockade demonstrated significantly greater antitumor efficacy compared to tucatinib alone (Figure 4A, p=0.0079) and increased survival (Figure 4B, p=0.05).

[0238] Example 4: Tucatinib promotes immune activation in HER2+-positive breast cancer and synergizes with PD-1 / PD-L1 blockade Cell lines and mouse patient-derived xenograft models. The mouse cell line H2N113 was cultured in RPMI medium containing 10% FBS. This HER2-positive mouse cell line was generated from a transgenic female mouse on a BALB / C MMTV ErbB2 / Neu background. Fo5 (MMTV-human HER2) tumor was obtained. Two human cell lines expressing HER2 were used for in vitro experiments: BT474 (ATCC catalog number: HTB-20) and SKBR3 (ATCC catalog number: HTB-30). BT474 cells are estrogen and progesterone receptor positive, HER2 amplified, and maintained in RPMI medium containing 10% FBS. SKBR3 cells are estrogen and progesterone receptor negative, HER2 amplified, and maintained in DMEM medium containing 10% FBS.

[0239] Drugs. For in vitro experiments, tucatinib was dissolved in DMSO at a concentration of 10 mM. For in vivo experiments, tucatinib was dissolved in 0.5% methylcellulose at the required concentration and stored at 4°C for up to 2 months. Tucatinib was administered by oral gavage once daily at doses of 25, 50, or 100 mg / kg in vivo, as indicated. Trastuzumab was stored at 4°C, diluted in sterile PBS, and administered intraperitoneally at a dose of 30 mg / kg, followed by weekly doses of 15 mg / kg. Mouse-specific antibodies against anti-PD-1, anti-PD-L1, and isotype controls (2A3, LTF2) were purchased from BioXcell and administered intraperitoneally at 200 μg per mouse twice weekly for 2 weeks. For in vivo studies, all antibodies were diluted in sterile PBS.

[0240] Growth inhibition assay. GI of tucatinib against each cell line 50 To obtain values, cell viability was assessed across a wide range of doses. Cells were plated in white-walled 96-well plates and treated with logarithmically increasing doses of tucatinib. Cells were incubated at 37°C for 72 hours, and cell viability was determined based on quantification of the CellTitre-Glo® assay (Promega) at a 1:3 dilution and luminescence readings using Cytation™ (BioTek). Dose-response curves were calculated using GraphPad Prism version 8.1.0 for macOS®. All experiments were performed at least in triplicate and GI data were analyzed. 50 The average value was used to calculate the value.

[0241] CFSE proliferation assay. Human PBMCs were isolated and incubated overnight in RPMI and 10% FBS. Cells were then stained with CFSE according to the manufacturer's protocol (Thermo Fisher). 1 × 10 cells were cultured at 1 × 10 5Cells were seeded into 96-well plates with or without anti-CD3 (OKT3; 1:1000) / anti-CD28 beads (Thermo Fisher Scientific) and increasing doses of tucatinib (zero to 4 μM). After 96 hours, cells were stained with anti-CD3 (UCTH1; 500 ng / mL), anti-CD4 (clone OKT4, Biolegend; 500 ng / mL), and anti-CD8a (clone HIT8a, Biolegend; 500 ng / mL). Unstimulated stained cells served as a control, and CD4 and CD8 T cell population doublings were determined by integrating the CFSE+ peak. Analysis was performed using FlowJo™ software.

[0242] Western blot analysis. For Western blot analysis, CD8+ and CD4+ T cells were isolated from human PBMCs. 5 × 10 per condition. 6T cells were added to 6-well plates precoated with anti-CD3 (1 μg / mL) and treated with either anti-CD28 (0.5 μg / mL), anti-CD28 and tucatinib (10 nM), or anti-CD28 and tucatinib (1.6 μM). Pellets were dissolved 15 minutes or 1 hour after treatment using radioimmunoprecipitation assay (RIPA) buffer. Primary antibodies used for immunoblotting were purchased from Cell Signaling Technologies (Danvers, MA, USA) or Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA): p-ERK1 / 2 (Thr202 / Tyr204; #9101, 1:1000, 42 / 44 kDa), p-AKT (Ser473; D9E #4060, 1:1000, 65 kDa), p-PI3K (Tyr458 / Tyr199; #4228, 1:1000, 85 / 55 kDa), p-ZAP70, p-ITK (Tyr512, #PA5-64523, 1:1000, 72 kDa), p-Src (Tyr416, #2101, 1:1000, 60 kDa), p-Lck (Tyr505, #2752, 1:1000, 56 kDa), and GAPDH loading control (ab-9484, 1:10,000, 40 kDa; Abcam, Cambridge, UK). HER2-positive human cell lines BT474 and SKBR3 and murine cell line H2N113 were treated with tucatinib (7 nM, 35 nM, or 50 nM, respectively) for 1, 3, 6, 24, and 72 hours. The secondary antibody used for chemiluminescent signal detection was α-rabbit HRP IgG (Santa Cruz; sc-2005, 1:3000).

[0243] Genomic analysis of mouse samples. RNA was extracted from Fo5 tumors treated in vivo with tucatinib at 50 mg / kg or vehicle (methylcellulose, 0.5%) for 10 days using TRIzol® Reagent with the PureLink® RNA Mini Kit (Invitrogen™, Thermo Fisher Scientific, Waltham, MA, USA). The quantity and integrity of total RNA were confirmed using a TapeStation 2200 (Agilent Technologies), and 500 ng was used for library preparation according to standard protocols (NEBNext Ultra II Directional RNA Library Prep Kit for Illumina and NEBNext Poly(A) mRNA Magnetic Isolation Module, NEB). Indexed libraries were pooled and sequenced on a NextSeq500 flow cell (Illumina), generating 25–50 million paired-end 75-bp reads per sample. Microarray data preprocessing and quantile normalization were performed using the AFFY package in R. From the normalized RNA intensities, unbiased differential expression analysis and short gene lists (FDR < 0.05) were generated using the LIMMA package in R. Differentially expressed genes were used for pathway and molecular function enrichment analysis in MetCore GeneCo. For gene set enrichment analysis, GSEA software was used with normalized RNA intensities. The false discovery rate was set to < 10%. Top gene pathways were selected based on a P value < 0.05 and a fold change > 1.5. All analyses were performed using R version 3.5.0. Gene sets in the differential expression heatmap included 10 interferon-γ genes, 28 preliminary expanded immunity genes, 18 T cell inflammation genes, and a 6-gene T-effector signature set, all of which are associated with PD-1 or PD-L1 blockade in various tumor types, including breast cancer.

[0244] In vivo mouse studies. Six to eight-week-old female MMTV / Balb / c and FVB mice were used in the experiments. Treatment groups consisted of n = 5 to 8 mice per group. For in vivo experiments using the H2N113 HER2-positive trastuzumab-sensitive tumor model, 5 × 10 5 The cells were suspended in phosphate-buffered saline and injected as a single cell suspension in a volume of 100 μL subcutaneously into the right flank of female MMTV-Balb / c mice. For in vivo experiments using the Fo5 HER2-positive trastuzumab-resistant tumor model, approximately 1 mm 3 Tumor fragments were surgically implanted into the fourth mammary fat pad of female FVB mice. Randomization and treatment were performed on tumors between 40 and 80 mm in size. 3 In the H2N113 tumor model, tumor size reached 60–120 mm approximately 10 days after inoculation. 3 In the Fo5 tumor model, tumor volume was calculated using the formula (length x width). 2 ) / 2, where length and width refer to the major and minor dimensions collected at each measurement. After tumor establishment and randomization into treatment groups, mice were treated with (1) vehicle control (methylcellulose 0.5%), (2) tucatinib (25, 50, or 100 mg / kg administered orally once daily), (3) trastuzumab alone (30 mg / kg dose followed by 15 mg / kg weekly intraperitoneally), (4) anti-PD-1 alone (200 μg intraperitoneally), (5) isotype 2A3 alone (200 μg intraperitoneally), (6) anti-PD-L1 alone (200 μg intraperitoneally), (7) isotype LTF2 alone (200 μg intraperitoneally), or (8) two-drug combinations of tucatinib and either trastuzumab, anti-PD-1, isotype 2A3, anti-PD-1, or isotype LTF2. Immunotherapeutic agents and isotype controls were delivered on days 0, 4, 8, and 12 in both models. Tumor volumes were measured twice weekly with calipers. Survival was monitored and tumors were removed within the ethical limit of 1500 mm. 3 It was decided when it reached

[0245] Flow cytometry analysis. For ex vivo studies, tumors were dissected, mechanically minced, and passed through a 70-μm filter. Cells were then resuspended in 30 μg / mL DNAse (Sigma-Aldrich) followed by Fc block (clone 2.4g2). Single-cell suspensions were then stained with antibody cocktails for various TIL subsets. In some experiments, isolated cells were stimulated with phorbol 12-myristate 13-acetate (PMA; 50 ng / mL) and ionomycin (1 μg / mL; Sigma-Aldrich) in the presence of GolgiPlug (BD Biosciences; 1:1000) and GolgiStop (BD Biosciences; 1:1500) for 3–4 hours prior to flow cytometry analysis. Samples were analyzed by FACS using either Fixable Yellow or Zombie Red to distinguish live and dead cells. BD fluorescent spherical counting beads were added to the cocktail before sample running.

[0246] Statistical Analysis. All statistical analyses were performed using Prism (version 9, GraphPad Software, Inc.). Data are presented as + / - SEM.

[0247] Results. As shown in Figures 5A-5C, in vitro, tucatinib demonstrated dose-dependent cell growth inhibition in HER2-positive human (BT474, Figure 5A and SKBR3, Figure 5B) and murine (H2N113, Figure 5C) trastuzumab-sensitive breast tumor cell lines, with a GI ≥ 72 h. 50 was in the nanomolar range (da...

Claims

1. 1. A pharmaceutical composition comprising tucatinib, or a salt or solvate thereof, for use in a method of treating a solid tumor in a subject, said pharmaceutical composition being for administration in combination with an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death-1 (PD-1) and inhibits PD-1 activity.

2. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof for use in a method for treating a solid tumor in a subject, the pharmaceutical composition being for administration in combination with tucatinib, or a salt or solvate thereof, wherein the antibody binds to programmed death-1 (PD-1) and inhibits PD-1 activity.

3. the anti-PD-1 antibody or antigen-binding fragment thereof a) comprising a complementarity determining region (CDR) of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021 and CS1003, or a biosimilar thereof; b) comprising a heavy chain variable region and a light chain variable region of an antibody or antigen-binding fragment selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021 and CS1003, or a biosimilar thereof; and / or c) selected from the group consisting of pembrolizumab, nivolumab, Amp-514, tislelizumab, cemiplimab, TSR-042, JNJ-63723283, CBT-501, PF-06801591, JS-001, camrelizumab, PDR001, BCD-100, AGEN2034, IBI-308, BI-754091, GLS-010, LZM-009, AK-103, MGA-012, Sym-021 and CS1003, or biosimilars thereof; The pharmaceutical composition according to claim 1 or 2.

4. The pharmaceutical composition of claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered intravenously.

5. A pharmaceutical composition comprising tucatinib or a salt or solvate thereof, said pharmaceutical composition for use in a method for treating a solid tumor in a subject, said pharmaceutical composition for administration in combination with an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death ligand-1 (PD-L1) and inhibits PD-L1 activity.

6. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, wherein the antibody binds to programmed death ligand-1 (PD-L1) and inhibits PD-L1 activity, the pharmaceutical composition for use in a method of treating a solid tumor in a subject, the pharmaceutical composition for administration in combination with tucatinib, or a salt or solvate thereof.

7. the anti-PD-L1 antibody or antigen-binding fragment thereof a) comprising a complementarity determining region (CDR) of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof; b) comprising the heavy and light chain variable regions of an antibody or antigen-binding fragment selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvaforimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or a biosimilar thereof; and / or c) selected from the group consisting of atezolizumab, BMS-936559, durvalumab, avelumab, emvafolimab, CK-301, CS-1001, SHR-1316, CBT-502, and BGB-A333, or biosimilars thereof; The pharmaceutical composition according to claim 5 or 6.

8. The pharmaceutical composition of claim 5 or claim 6, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is administered intravenously.

9. The pharmaceutical composition of any one of claims 1, 2, 5 and 6, wherein the solid tumor is a HER2+ solid tumor.

10. The solid tumor expresses a mutated form of HER2, and the HER2 mutation is a) contains at least one amino acid substitution, insertion or deletion compared to the amino acid sequence of SEQ ID NO:1; b) is an activating mutation; c) a mutation in the extracellular domain, the kinase domain, or the transmembrane / juxtamembrane domain, or any combination thereof; d) a mutation in the extracellular domain selected from the group consisting of G309A, G309E, S310F, S310Y, C311R, C311S, and C334S; e) a mutation in the kinase domain of an amino acid residue selected from the group consisting of Y772, G776, G778, and T798; f) G776 YVMA insertion; g) a mutation in the kinase domain selected from the group consisting of T733I, L755P, L755S, I767M, L768S, D769N, D769Y, D769H, V777L, V777M, L841V, V842I, N857S, T862A, L869R, H878Y, and R896C; h) a mutation in the kinase domain at amino acid residue V697; and / or i) a mutation in the transmembrane / juxtamembrane domain selected from the group consisting of S653C, I655V, V659E, G660D, and R678Q; 7. The pharmaceutical composition according to any one of claims 1, 2, 5 and 6.

11. The solid tumor is a) does not have HER2 amplification, where the absence of HER2 amplification is determined by immunohistochemistry (IHC); b) having a HER2 amplification score of 0 or 1+, wherein said HER2 amplification score is determined by immunohistochemistry (IHC); or c) have less than a two-fold increase in HER2 protein levels; The pharmaceutical composition according to claim 10.

12. The pharmaceutical composition of claim 10, wherein the solid tumor comprises HER2 overexpression / amplification.

13. 7. The pharmaceutical composition of any one of claims 1, 2, 5 and 6, wherein the solid tumor is a) a metastatic solid tumor, b) locally advanced, and / or c) unresectable.

14. 7. The pharmaceutical composition according to any one of claims 1, 2, 5 and 6, wherein the solid tumor is selected from the group consisting of cervical cancer, uterine cancer, gallbladder cancer, bile duct cancer, urothelial cancer, lung cancer, breast cancer, gastroesophageal cancer and colorectal cancer.

15. 15. The pharmaceutical composition of claim 14, wherein the breast cancer is a) HER2+ breast cancer, and / or b) hormone receptor positive (HR+) breast cancer.

16. The pharmaceutical composition of claim 14, wherein the lung cancer is non-small cell lung cancer.

17. The pharmaceutical composition of claims 1, 2, 5 and 6, wherein the solid tumor is sensitive to trastuzumab or resistant to trastuzumab.

18. The pharmaceutical composition of claims 1, 2, 5 and 6, wherein the tucatinib or a salt or solvate thereof is orally administered to the subject at a dose of about 150 mg to about 650 mg once or twice daily.

19. The pharmaceutical composition of claims 1, 2, 5 and 6, further comprising administering to the subject one or more additional therapeutic agents for treating the solid tumor.

20. the one or more additional therapeutic agents is an anti-CTLA4 antibody or antigen-binding fragment thereof; the anti-CTLA4 antibody or antigen-binding fragment thereof a) containing the CDRs of ipilimumab or its biosimilars; b) comprises the heavy and light chain variable regions of ipilimumab or a biosimilar thereof, and / or c) ipilimumab or its biosimilars; 20. The pharmaceutical composition of claim 19.

21. The object is a) having one or more adverse events and an additional therapeutic agent is further administered to eliminate or reduce the severity of said one or more adverse events; or The pharmaceutical composition of claims 1, 2, 5 and 6, wherein b) there is a risk of developing one or more adverse events, and an additional therapeutic agent is further administered to prevent or reduce the severity of said one or more adverse events, and said one or more adverse events are grade 3 or higher adverse events and / or are serious adverse events.

22. The pharmaceutical composition of claims 1, 2, 5 and 6, wherein the subject is a human.